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Summary 
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults of 
the Western world. It is a malignancy characterized by an accumulation of CD5 positive 
B-cells in blood and lymphoid organs. CLL is a very heterogeneous disease, where 
molecular subgroups display striking differences in treatment response and prognosis. A 
greater BCR signaling capacity and a loss of p53 signaling activity confer a poor 
prognosis. While the higher BCR signaling activity seen in CLL with unmutated IGHV 
genes supports tumor cell survival, p53 aberrations mediate resistance towards standard 
therapy. The aim of this work was to characterize the involvement of non-coding RNA in 
these two key signaling pathways of CLL cell survival and resistance. 
Small RNA sequencing was applied to comprehensively assess microRNA (miRNA) and 
other non-coding RNA expression in peripheral blood mononuclear cells of 35 CLL 
patients. miRNAs were identified that display IGHV mutation status dependent 
expression, and the transcript levels of 15 miRNAs predicted IGHV mutation status with 
82% accuracy. By abrogation of BCR signaling in vitro using the small-molecule inhibitor 
ibrutinib, the expression of miR-320c, miR-1246, miR-484, miR-17-5p, miR-155-3p and 
miR-27a-5p was found to be BCR signaling dependent, suggesting a role in mediating 
CLL cell survival. The basal expression of 10 miRNAs was associated with ibrutinib 
sensitivity in vitro, implicating an involvement of these miRNAs in the regulation of BCR 
signaling.  
It was hypothesized that p53-dependent ncRNAs could be identified by comparison of 
CLL samples with or without TP53 mutation/deletion for their ncRNA expression changes 
upon DNA damage-triggered p53 induction. In addition to miR-34a, a set of further 
miRNAs was found to be TP53 status dependently induced (particularly miR-182-5p, 
miR-7-5p and miR-320d/c). Beyond miRNAs, the present data demonstrate p53-
dependent expression of the long non-coding RNAs lincRNA-p21 (long intergenic non-
coding RNA p21) and NEAT1 (nuclear enriched abundant transcript 1) upon DNA 
damage and direct p53 activation with nutlin-3. p53-dependent induction of expression 
was further proven in a panel of Burkitt’s lymphoma (BL) cell lines including cell lines 
with genetically engineered knockout or knockdown of p53. p53 ChIP demonstrated 
direct binding of p53 to the NEAT1 promoter. This provides first evidence of p53-
dependent regulation of long non-coding RNAs in CLL and BL. The discovery of p53-
dependent NEAT1 induction, which is an integral part of nuclear paraspeckles, paves the 
way for further research on the role of paraspeckles in tumor cell apoptosis and 
resistence. The current work identifies additional components of the p53-dependent DNA 
damage response in lymphoma.  
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The results of these studies provide new insight into the involvement of miRNAs and 
lncRNAs in two key signaling pathways regulating cell survival and treatment resistance 
in CLL and lymphoma.  
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Zusammenfassung 
Die chronisch lymphatische Leukämie (CLL) ist die häufigste Form der Leukämie in 
Erwachsenen der westlichen Hemisphäre. Charakteristisch für diese maligne 
Erkrankung ist die Akkumulation von CD5 positiven B-Zellen im Blut und in den 
Lymphorganen. CLL ist eine sehr heterogene Erkrankung, in der molekulare 
Subgruppen bemerkenswerte Unterschiede im Hinblick auf Therapieansprechen und 
Prognose zeigen. Eine erhöhte Kapazität des B-Zell-Rezeptor (BCR) Signalwegs wie 
auch ein Verlust der Aktivität des p53-Signalwegs bedingen eine schlechte Prognose. 
Während unmutierte IGHV Gene über eine höhere Aktivität des BCR Signalwegs zu 
einem verbesserten Überleben der Tumorzellen führen, vermitteln Aberrationen in dem 
Tumorsuppressor p53 Therapieresistenz. Ziel dieser Arbeit war es, die Beteiligung von 
nicht-kodierenden RNAs (ncRNAs) in diesen beiden für das Überleben und die 
Resistenz von CLL-Tumorzellen zentralen Signalwegen zu charakterisieren.   
Um die Expression von microRNA (miRNA) und weiteren nichtkodierenden RNA 
(ncRNA) in mononukleären Zellen des periphären Blutes von 35 CLL Patienten 
umfassend zu quantifizieren, wurden kurze RNA Transkripte (small RNA) sequenziert. 
Es wurden IGHV-Mutationsstatus abhängig exprimierte miRNAs identifiziert, und anhand 
der Signatur von 15 miRNAs ließ sich der IGHV Mutationsstatus in 82% der Proben 
korrekt bestimmen. Eine Unterbrechung des BCR Signalwegs durch in vitro-Behandlung 
mit dem small-molecule Inhibitor Ibrutinib führte zur differenziellen Expression von miR-
320c, miR-1246, miR-484, miR-17-5p, miR-155-3p und miR-27a-5p, was deren 
Abhängigkeit von einem aktiven BCR demonstriert und eine Beteiligung an diesem 
überlebensfördernden Signalweg nahelegt. Die Assoziation der basalen Expression von 
10 miRNAs mit in vitro Ibrutinib-Sensitivität der Proben impliziert eine Mitwirkung dieser 
miRNAs an der Regulation der BCR Signalaktivität.  
p53-abhängige ncRNAs wurden durch einen Vergleich der Expressionsänderungen 
zwischen TP53 wildtyp und TP53 mutierten/deletierten CLL-Proben nach p53 Induktion 
durch DNA-Schädigung identifiziert. Zusätzlich zu miR-34a war die Expression einer 
Gruppe weiterer miRNAs (insbesondere miR-182-5p, miR-7-5p, miR-320d/c) abhängig 
vom TP53 Mutationsstatus. Über miRNAs hinaus enthüllten die Daten dieser Arbeit die 
p53-abhängige Expression der langen nicht-kodierenden RNAs (lncRNAs) lincRNA-p21 
(long intergenic non-coding RNA p21) und NEAT1 (nuclear enriched abundant transcript 
1) nach DNA-Schädigung sowie nach direkter p53-Aktivierung mittels Nutlin-3 in CLL. 
Deren p53-abhängige Induktion über CLL hinaus wurde anhand einer Auswahl an 
Burkitt’s Lymphom (BL) Zelllinien, deren p53 Expression teils durch p53 knockout oder 
knockdown kontrolliert worden war, nachgewiesen. Durch p53 ChIP konnte die direkte 
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Bindung von p53 an den NEAT1 Promoter demonstriert werden. Damit wurde erstmals 
die p53-abhängige Regulation langer nicht-kodierender RNAs in CLL und BL gezeigt. 
Die Entdeckung der p53-abhängigen Regulation von NEAT1, einem zentralen 
Bestandteil nukleärer Paraspeckles, bahnt weiteren Arbeiten zur Rolle der Paraspeckles 
in Apoptose und Resistenz von Tumorzellen den Weg. Die vorliegende Arbeit identifiziert 
neue Komponenten der p53-abhängigen Antwort auf DNA-Schäden in malignen 
Lymphomen.   
Die Ergebnisse dieser Arbeit bieten neue Einblicke in die Beteiligung von miRNAs und 
lncRNAs an zwei für die Regulation von zellulärem Überleben und Therapieresistenz 
zentralen Signalwegen in der CLL und malignen Lymphomen. 
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1 Introduction 
 
1.1 Cancer 
1.1.1 Characteristics of cancer  
Tumor cells arise from normal cells through an evolutionary process that eventually 
enables them to evade the body’s control mechanisms and multiply at unphysiologic 
frequency1. The characteristics obtained by the malignant cells have been summarized 
as the ‘hallmarks of cancer’ by Hanahan and Weinberg in 20002, revised in 20113 and 
illustrated in Figure 1. These acquired functional capabilities including the resistance to 
cell death, replicative immortality or invasion and metastasis are present in virtually all 
cancers. However, the biological mechanisms underlying their development and their 
chronological sequence vary greatly in different cancer types, among tumors of the same 
entity, and even among the cells composing a tumor2,3.  
Cancer is a disease of genetic and epigenetic alterations affecting genes that regulate 
cellular integrity and tissue homeostasis4-8. Depending on the outcome of their activation, 
those genes are termed tumor suppressor genes or oncogenes.  
 
 
 
Figure 1. The hallmarks of 
cancer. Acquired capabilites of 
tumor cells as summarized by 
Hanahan and Weinberg, 20113. 
 
  
1.1.2 Oncogenes and tumor suppressor genes 
Oncogenes develop from normal, non-cancerous proto-oncogenes through mutation, 
translocation, amplification or epigenetic mechanisms (‘gain of function’) to promote 
tumorigenesis. As such, they are frequently involved in cellular proliferation and signal 
transduction. A single, monoallelic, alteration in a proto-oncogene can be sufficient for 
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transformation, illustrating the dominant effect of oncogene activation. Myc (c-Myc), for 
example, is a transcription factor which is frequently found overexpressed in cancer 
through gene amplification, leading to a higher expression of genes involved in cell cycle 
progression including cyclin A and E9,10 . In ~80% of Burkitt’s Lymphoma, a translocation 
(mostly t(8;14)(q24;q32)) puts c-Myc under the control of a strong immunoglobulin heavy 
chain locus promoter, resulting in overexpression of the oncogene10. Supported by 
accompanying second-hit mutations which counterbalance the pro-apoptotic pathways 
(e.g. p53) activated to safeguard the cell against MYC-induced transformation, mice 
transgenic for this translocation almost invariably develop aggressive lymphomas11-13.  
In contrast, tumor suppressors prevent malignant transformation. Here, a decreased 
activity (‘loss of function’) promotes, i.e. increases the likelihood of, carcinogenesis. As it 
typically requires the presence of only a single functional gene for its activity, tumor 
suppressor genes are recessive, requiring ‘two-hit’ inactivation of both alleles8,14. 
Inheritance of one mutant allele can increase tumor susceptibility, as only one further 
mutation is needed to inactivate gene function8. This is often observed in familial cancer 
syndromes. Tumor suppressor genes are involved in cellular processes such as cell 
cycle checkpoint responses, DNA damage detection and repair, differentiation and tumor 
angiogenesis. The retinoblastoma gene (RB) which is frequently found deleted in 
hereditary and sporadic retinoblastoma was the first tumor suppressor gene to be 
identified14. By inhibiting e.g. E2F, a major negative regulator of the cell cycle, it prevents 
proliferation by blockade of G1/S-phase progression15. p53 is a key tumor suppressor 
and is inactivated by deletions and/or somatic mutations in more than 50% of cancers8. It 
is an exception to the ‘two-hit’ rule, as mutant p53 protein can exert a dominant negative 
effect by preventing the activity of wild-type protein from the second allele16. p53 causes 
G1 phase arrest and apoptosis upon DNA damage, guarding the cell against genotoxic 
insult17. Multiple stresses inducing p53 and downstream outcomes have been described, 
emphasizing its key role in tumor suppression (delineated in section 1.3.2.2).  
1.2 B-cells and B-cell malignancies 
1.2.1 B-cells and B-cell receptor development  
The human immune system is composed of an innate and an adaptive part. The innate 
immune system quickly reacts as first-line defense to microbial pathogens in a generic 
way. The adaptive immune system relies on antigen-specific recognition by receptors 
expressed on the surface of clonally expanded B- and T-cells. It triggers targeted 
responses against pathogens, which take several days or weeks to develop and 
generate long lasting immunity. B-cells play a major role within the adaptive immune 
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system by producing specific antibodies, presenting antigens and generating memory 
cells that can be activated upon repeated infection with the same pathogen18. 
B-cell development and maturation starts from stem cells within the bone marrow and 
occurs through numerous stages that are characterized by changes in the specific 
structure of the B-cell receptor (BCR). This cell-membrane bound surface 
immunoglobulin (sIg) consists of two identical heavy-chain (H) and two identical light-
chain (L) polypeptides, which are covalently linked by disulphide bridges and display a 
specific antigen-binding site. The corresponding genes occur as separate fragments that 
are assembled into the active gene by V(D)J recombination19,20. During early B-cell 
development in the bone marrow, first the H region is remodeled through randomly 
joining together one of about 50 functional variable (VH) genes, one of about 27 
functional diversity (DH) and one of 6 joining (JH) gene segments. The L region is 
similarly rearranged by combination of the VL and JL genes, generating high receptor 
diversity. Only B-cells expressing a functional, non-autoreactive BCR differentiate into 
mature, naïve B-cells and leave the bone marrow21. Subsequently, they can participate 
in immune responses upon antigen binding to the BCR in the peripheral blood, but more 
frequently, antigen-activated B-cells undergo T-cell-dependent immune responses and 
clonal expansion in the germinal centers (GCs). GCs are specialized structures in 
secondary lymphoid tissues such as the lymph nodes and spleen, illustrated in Figure 2. 
Here, the Ig genes are further modified by somatic hypermutation occurring at the 
complementarity determining regions, resulting in mutated IgHV (immunoglobulin heavy 
chain variable region) genes and tremendous BCR diversity. While most mutations result 
in reduced antigen binding affinity of the BCR to the cognate antigen leading to apoptotic 
cell death, cells with mutations conferring enhanced affinity are positively selected and 
can undergo class-switch recombination. Here, the original constant regions (C) of the 
BCR, usually IgM or IgD, can be replaced to IgG, IgE or IgA by chromosomal 
recombination. Subsequently, B-cells can differentiate into memory B-cells or antibody 
producing plasma cells and leave the GC20,22. 
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Figure 2. B-cell differentiation in the germinal center (GC). Antigen-activated B-cells 
differentiate into centroblasts that undergo clonal expansion and somatic hypermutation (SHM) in 
the dark zone, introducing base-pair changes into the IgV region of the heavy and light chain. 
Centroblasts differentiate into centrocytes and move to the light zone where they are selected for 
improved BCR antigen affinity, supported by antigen presentation by T-cells and follicular 
dendritic cells (FDCs). Positively selected B-cells can undergo class-switch recombination (CSR) 
and differentiate into memory B-cells or plasmablasts to be released from the GC. Centrocytes 
producing an unfavourable BCR upon SMH (low affinity, auto-reactivity) undergo apoptosis (Klein 
et al., 2008).   
 
1.2.2 B-cell malignancies and mechanisms of lymphomagenesis 
The World Health Organization (WHO) classifies lymphomas into Hodgkin- and non-
Hodgkin Lymphoma, the latter encompassing mature B-cell neoplasms, mature T-cell 
and NK (natural killer cell) neoplasms and posttransplantation lymphoproliferative 
disorders23. B-cells account for about 95% of lymphomas20. In the Western world, about 
19 new cases of non-Hodgkin lymphoma are diagnosed in 100,000 individuals annually, 
making it the 7th most frequent cancer diagnosed and the 9th most frequent cause of 
cancer death in the U.S.24,25. B-cell lymphomas are classified according to the 
developmental stage of their cell of origin and thus sub-divided into about 20 different 
types23. The most common (in the U.S.) are diffuse large B-cell lymphoma (DLBCL), 
follicular lymophoma (FL) and chronic lymphocytic leukemia (CLL). By gene expression 
profiling and surface marker phenotyping, the assignment of tumor cells to a distinct cell 
of origin is for some types very clear (Figure 3). CLL however is a remarkably 
heterogeneous disease, for which various cells of origins are debated and no consensus 
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has been found to date26,27. In about half of the patients, CLL cells carry unmutated IgHV 
genes, suggesting pre-GC B-cells as normal counterpart. In the remaining half they carry 
somatically mutated IgHV genes, suggesting B-cells past the GC response as origin28,29. 
This distinction is of great biological and therapeutic relevance.  
B-cell transformation is promoted by at least four mechanisms: I) Somatic mutations 
and/or chromosomal aberrations, II) BCR signaling, III) the microenvironment and/or VI) 
viral infection. 
 
Figure 3. Cellular origin and frequent genetic aberrations in non-Hodgkin lymphoma. B-cell 
malignancies arise at different stages of B-cell development. Frequently, genetic aberrations 
contribute to pathogenesis and characterize the type of B-cell lymphoma. The germinal center is 
surrounded by a mantle zone (follicle) of naïve, mostly CD5+ B-cells and a marginal zone in the 
spleen (but not in lymph nodes), a B-cell rich zone between B-cell follicles and the T-cell area. (B-
ALL, B-cell acute lymphocytic leukemia; CLL, chronic lymphocytic leukemia; SMZL; splenic 
marginal zone lymphoma; MCL, mantle cell lymphoma; DLBCL, diffuse large B-cell lymphoma; 
MALT, mucosa associated lymphoid tissue (Rickert 2013, modified).  
 
Most lymphomas are derived from GC- or post-GC B-cells. The GC constitutes a highly 
proliferative environment to generate large amounts of immunoglobulin for antigen 
elimination30. This background supports the occurrence and accumulation of 
chromosomal rearrangements and somatic mutations. Some malignancies are 
characterized by specific cytogenetic abnormalities. Reciprocal chromosomal 
translocations involving an Ig locus and a proto-oncogene constitute a hallmark of B-cell 
lymphoma (Figure 3). Consequently, the proto-oncogene comes under the control of the 
active Ig locus, causing its constitutive overexpression which drives the disease30,31. 
Others, such as CLL, are not distinguished by a common genetic defect.  
Another pivotal role in supporting lymphomagenesis is taken by the BCR. Ablation of 
BCR expression on mature B-cells in mice leads to apoptosis, establishing BCR 
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signaling as a determinant of B-cell survival32,33. There is strong evidence that stimulation 
by antigen binding contributes to survival and proliferation of lymphoma cells. Whether 
this survival signal is supplied by autonomous or antigen-induced activation is a matter of 
ongoing debate20.  
An important role of the microenvironment (i.e. nurse-like cells, T-cells, mesenchymal 
stromal cells and matrix factors34) for the survival and/or proliferation of transformed B-
cells is demonstrated by lack in vitro proliferation of many lymphoma cells without its 
support. FL cells, for example, require co-culture with CD4+T-cells or stromal cells35, 
whereas CLL cells need support by stromal cells (or their secreted factors) and CD40 
ligand to keep in culture or proliferate, respectively36-38. In part, this interaction involves 
signaling through the BCR. 
Lastly, B-cell transformation can be caused by viral infection, most frequently by Epstein-
Barr virus (EBV), a herpes virus found in almost all endemic Burkitt’s lymphoma and 
post-transplant lymphoma, and about 40% of classical Hodgkin’s lymphoma39-41. EBV-
encoded latent genes induce transformation by altering cellular gene transcription and 
constitutively activating key cell-signaling pathways41. 
 
1.3 Chronic Lymphocytic Leukemia (CLL) 
Chronic lymphocytic leukemia (CLL) is characterized by the progressive accumulation of 
immunoincompetent CD5+ B-lymphocytes, mostly arrested in G0/G1 phase of the cell 
cycle, in blood, bone marrow, lymph nodes and spleen42. It represents about 25-30% of 
all leukemias, making it the most common adult leukemia in Western countries43. CLL is 
diagnosed in 3.9 per 100 000 individuals in the U.S. annually at a median age of 72, and 
the incidence is nearly twice as high in men than in women44. While patients are usually 
asymptomatic at diagnosis, lymph node enlargement, constitutional symptoms and bone 
marrow failure are common symptoms at later stages. CLL is a very heterogeneous 
malignancy. Whereas it is indolent in most cases and can be monitored over years 
without treatment (‘watch and wait’ strategy), it is more aggressive in others who show a 
poor response to standard treatment and a survival of less than two years45-47.  
Various pathogenic mechanisms have been discussed, which include chromosomal 
aberrations46,48, gene mutations49-51, altered DNA methylation52, deregulated (micro) RNA 
expression levels53, antigen-triggered and autonomous BCR signaling54,55 as well as the 
microenvironment56. The identification of molecular subgroups has greatly improved the 
understanding of underlying biology, the prediction of clinical course of the disease and 
the development of more stratified treatment approaches. 
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1.3.1 Molecular subgroups 
1.3.1.1 IGHV mutation status 
CLL can be separated into cases that have mutated IGHV genes and those with 
unmutated IGHV genes (defined as at least 98% sequence homology with the germline 
IGHV genes). The clinical and biological behaviour of the two subsets differs 
substantially, with patients of unmutated IGHV showing significantly poorer survival 
(Figure 4)28,29,42,57. 
 
 
Figure 4. CLL patient survival by 
IGHV mutation status. Patients with 
IGHV unmutated genes show poorer 
survival than those with mutated IGHV 
(Zenz et al., 2010). 
 
While this can in part be explained by the greater likelihood of IGHV-unmutated CLLs to 
carry high-risk genetic lesions such as 11q23 and 17p1357,58, the prime underlying 
reason is a differential signaling capacity through the BCR. BCR signaling is reduced in 
IGHV-mutated CLLs59 (see also section 1.3.2.1). Unmutated CLLs additionally show 
higher expression levels of CD38 and tyrosine kinase zeta associated protein 70 
(ZAP70), which enhance BCR signaling60-62. In line with this, unmutated CLLs display a 
greater proliferative capacity in vivo, which is supported by the observation of reduced 
telomere lengths in those tumor cells63-65.  
 
1.3.1.2 Genomic aberrations 
Approximately 80% of CLL cases show aberrations in a few frequently affected 
chromosomal regions. A deletion on chromosome 13q14.3 is the most frequent one 
(~55%, Table 1). Still, CLL tumor cells do not show a typical, causative somatic mutation 
pattern.  
The minimally deleted region on 13q14.3 encodes two long non-coding genes (DLEU1 
and 2) as well as miR-15a and miR-16-1, which were the first microRNA (miRNA) genes 
to be found deleted in cancer53,66. The next most frequent aberration is a mutation and/or 
deletion of the ATM (ataxia telangiectasia mutated) gene encoding a kinase activating 
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p53 upon DNA damage, which in turn is central to the induction of cell cycle arrest, DNA 
repair and apoptosis.  
 
Table 1. The most frequent genomic aberrations in CLL overall, and in refractory cases.   
Genetic aberration Unselected (%) Refractory (%) 
1. del13q14 (miR-15a, miR-16-1) 5548 1967 
2. ATM mutation 12-1468,69 ? 
3. del11q23 (ATM)  12-1848,68 19-2067,70 
4. trisomy 12   16-1748,57 767 
5. NOTCH1 mutation 5-1271-73 1374 
6. TP53 mutation  7-1473,75,76 3774 
7. SF3B1 mutation 4-972,73 1874 
8. del17p13 (TP53) 7-957,75 30-3267,70,77 
 
Del13q14 (as sole aberration) confers a good prognosis (Table 1, Figure 5). In contrast, 
the presence of ATM aberrations or a deletion and/or mutation of TP53 encoding p53 on 
chromosome 17p13.1 associate with a particularly poor prognosis, since conventional 
chemoimmunotherapy often proves ineffective78. Consequently, ATM and TP53 
aberrations are frequent among in refractory patients (Table 1) and result in poor patient 
survival (Figure 5, see also section 1.3.2.2). The molecular pathomechanisms underlying 
other recurrent aberrations such as trisomy 12 and mutations of the membrane receptor 
NOTCH1 and splicing factor SF3B1 are less well understood79-81. 
 
 
 
Figure 5. Probability of 
survival from diagnosis in 
CLL patients of five genetic 
subgroups.   
(Dohner et al., 2000). 
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1.3.2 Two key signaling pathways in CLL cell survival and proliferation 
1.3.2.1 B-cell receptor signaling  
Signaling through the BCR may have different consequences depending on the stage of 
maturation and/or (co-)activation of the B-cell. The same signals may result in apoptosis 
of immature or self-reactive B-cells, but in proliferation of selected, foreign antigen-
specific mature cells82. In CLL, BCR signaling plays a vital role in the maintenance and 
expansion of the B-CLL clone, as indicated by a strong, constitutive activation of this 
signaling pathway56,83,84. Whether this activation is caused by specific (auto)antigens 
and/or cell-autonomous mechanisms is intensely debated. The concept of antigen-
triggered BCR signaling is supported by a strong bias in IGHV gene usage. Of the ~50 
functional human IGHV gene segments, only a selection is found highly enriched in CLL 
(e.g. VH1-69, VH3-21, VH3-07 and VH4-34)85. Moreover, in about 30% of CLL cases 
(both IGHV unmutated and mutated), the malignant cells express ‘stereotyped’ BCRs, 
i.e. the V regions of unrelated patients are nearly identical, indicating discrete antigens or 
structurally similar epitopes as disease drivers54,86. B-cells with mutated IGHV are 
thought to be selected and expanded by high-affinity binding to a restricted set of rare 
antigens that induce anergy87. In contrast, BCRs with unmutated IGHV sequences are 
considered polyreactive, enabling more frequent, low-affinity binding of the BCR and a 
higher BCR signaling activity59,87,88. This likely explains the higher tumor cell proliferation 
rates and poorer prognosis seen in CLL with unmutated IGHV.  
Recently, two studies additionally suggested ligand independent (‘tonic’), cell-
autonomous BCR activation in CLL by binding of the heavy-chain complementarity 
determining region (HCDR3) on one BCR to an internal epitope of a neighboring 
BCR55,89. 
In any case, BCR activation has a distinct outcome: On the one hand, it triggers cytokine 
secretion by the CLL cells, shaping the supportive microenvironment by attracting 
monocytes and T-cells38,90. On the other hand, a powerful survival program is elicited 
upon downstream signaling originating from the oligomerization of BCR components (i.e. 
sIg and CD79A CD79B heterodimers (Ig-α/Ig-β)) and Lyn-mediated phosphorylation of 
the CD79A and B cytoplasmic tails91-94 (Figure 6). The signal is further transmitted 
through a set of signaling pathways, particularly through spleen tyrosine kinase (SYK), 
Bruton’s tyrosine kinase (BTK) and phosphoinositide 3-kinases (PI3Ks)95 leading to the 
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Figure 6. CLL BCR signaling 
with focus on Bruton’s tyrosine 
kinase. BCR signaling results in 
the formation of a micro-
signalosome composed of VAV, 
PI3K, BTK, SH2 domain-containing 
leukocyte protein of 65 kDa 
(SLP65) and phospholipase C2γ 
(PLCγ2), resulting in an influx of 
Ca2+. This leads to activation of the 
transcription factors nuclear 
receptor of actiated T-cells (NFAT) 
and NF-κB as well as ERK. AKT is 
activated via PI3K, inhibiting 
forkhead box O (FOXO) 
transcription factors. BCAP, B cell 
adaptor for PI3K; BIM, BCL-2 
interacting mediator of cell death; 
CaM, calmodulin; CIN85, CBL-
interacting protein of 85 kDa; CN, 
calcineurin; DAG, diacylglycerol; GSK, glycogen synthase kinase; IκB, inhibitor of κB; IKK, inhibitor of 
NF-κB kinase;IP3, inositol trisphosphate; IP3R, IP3 receptor; PDK1, 3-phosphoinositide-dependent 
protein kinase 1; PIP3, phosphatidylinositol-3,4,5,-trisphosphate; PKC, protein kinase C (Hendriks et 
al. 2014, modified). 
 
activation of nuclear factor kappa light-chain enhancer of activated B-cells (NF-κB)56,96, 
protein kinase B/AKT97, and extracellular signal-regulated kinase (ERK)98 pathways. 
BTK has proven to be an attractive drug target. Its inhibition with the recently developed 
covalent small-molecule inhibitor ibrutinib (PCI-32765) leads to decreased NF-κB and AKT-
signaling and abrogation of CLL cell survival, and promises a major advance in CLL 
therapy97-100. As ibrutinib treatment resulted in a high frequency of durable remissions even in 
patients refractory to common chemotherapy in clinical trials up to stage III95,101,102, it has 
been approved in 2014 for the treatment of refractory CLL in the U.S.. In line with a higher 
BCR signaling capacity in IGHV unmutated CLL patients, those show a better treatment 
response than IGHV mutated CLLs95. Likewise, the PI3Kδ inhibitor idelalisib has reached 
approval for the treatment of relapsed CLL in the U.S. this year103,104, and a SYK inhibitor 
(fostamatinib) is in current development105,106. 
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1.3.2.2 The p53 pathway  
p53 is a key regulator of the cellular response to a broad range of stress signals 
including DNA damage and oncogene activation, as illustrated in Figure 7.  
 
 
Figure 7. Mechanisms of p53 activation and regulation of downstream targets, highlighting 
components aberrant in CLL. Various stresses induce signal mediators increasing the half-life 
of p53 by phosphorylation or inhibition of its MDM2-mediated ubiquitinylation. Modifications such 
as acetylation (Ac) and methylation (Me) can further stabilize the protein homotetramer, which 
binds to a DNA p53 response element (p53 RE) and recruits cofactors to regulate the 
transcription of a nearby gene. Hundreds of genes can be transactivated, mediating outcomes 
including DNA repair, cell cycle arrest and apoptosis. ATR, ataxia telangiectasia and Rad3-related 
protein; CHK1/2, checkpoint kinase 1 and 2; DDB2, damage-specific DNA-binding protein-2; 
GADD45α, growth arrest and DNA-damage inducible α; TRIM22, tripartite motif containing-22; 
Bax, BCL2-associated X protein (based on Riley et al. 2008, Zenz et al. 2010, Bieging et al., 
2014).   
 
In response to diverse cellular stresses that activate kinases such as ATM or inhibit the 
negative regulator MDM2 (double minute-2), p53 binds to p53 response elements (p53 
RE) in the promoter regions of p53 target genes to activate, or - more rarely - repress 
Introduction 
12 
 
their transcription. Via transducer molecules such as GADD45α, p21 (CDKN1A) or Bax it 
mediates DNA repair, cell cycle arrest and apoptosis, respectively, to prevent the 
accumulation of genetic aberrations and maintain cellular integrity107-110. This key 
suppressor of tumorigenesis is mutated or functionally inactivated across human 
malignancies, enabling tumor cells to escape apoptosis, cell cycle arrest and 
senescence108,109,111.  
In CLL, p53 aberrations have direct implications for disease management, as they 
associate with progressive disease and are a main determinant of chemorefractoriness, 
resulting in a median survival of 3-4 years92,93,70,112,113. 
p53 deletions (del 17p13) and/or TP53 mutations are present in about 10% of cases and 
up to 50% of refractory patients (Table 1). Deletions are monoallelic. In the majority of 
cases (>80%) the second allele is mutated114. TP53 mutation in absence of 17p13 is 
infrequent (4-5%), but confers a similar prognosis to the patient as biallelic TP53 
inactivation76,114, possibly due to the dominant negative effect of mutant over wild-type 
p5316,115. p53 aberrations are frequently subclonal, indicating an occurrence at later 
stages of tumor evolution. Beyond p53, further pathway members are often affected in 
CLL. Aberrations of ATM, the principal activator of p53 in the response to DNA double-
strand breaks, by a deletion of 11q22-23 and/or mutation result in impaired in vitro DNA 
damage responses and reduced overall and treatment-free patient survival68,69. However, 
genetic aberrations of p53 and ATM explain only about 50-70% of poor patient 
outcomes, and the reason for refractoriness in the remaining cases remains largely 
unclear. In part it could be attributed to a low expression of p53 target miR-34a, which is 
associated with refractory CLL even in the absence of p53 aberrations70,116.  
 
1.4 microRNAs and long intergenic non-coding RNAs  
1.4.1 Classification, biogenesis and function 
microRNAs 
microRNAs (miRNAs) represent a class of short, single-stranded non-coding RNAs of 
17-25 nucleotide (nt) length which post-transcriptionally regulate the expression of the 
majority of protein-coding genes117-119. miRNAs are abundant in many human cell types. 
Since the initial discovery of lin-4 and let-7 in C. elegans in 1993120, over 1800 human 
miRNAs have been annotated and listed in the miRNA reference database (miRBase 
v21). miRNAs are involved in the regulation of virtually all cellular processes including 
cell cycle, proliferation, apoptosis and differentiation121. Not surprisingly, their 
deregulation has been implicated in many diseases including cancer. 
Introduction 
13 
 
miRNA genes are transcribed by RNA polymerase II from intergenic, intronic or 
polycistronic loci, forming a miRNA precursor (pri-miRNA) of hairpin-shaped loop 
structure and several 100 nt length (see Figure 8). Processing by the Drosha-DGCR8 
complex yields a ~70 nt pre-miRNA hairpin, which is exported to the cytoplasm and 
cleaved by the Dicer-TRBP complex, generating imperfect miRNA duplexes of mature 
miRNAs. These are incorporated into Argonaute (Ago2) protein complexes, forming the 
RNA-induced silencing complex (RISC) which retains one of the mature miRNA strands. 
Depending on which arm of the precursor the miRNA originates from, the mature miRNA 
is assigned the suffix -3p (3’ arm) or –5p (5’ arm, e.g. miR-155-5p). This miRNA 
functions as a guide, directing RISC to partially complementary sites in target mRNAs, 
where it binds to the 3’ untranslated region. This results in silencing by translational 
inhibition, induced degradation and/or deadenylation of the respective mRNA122,123. 
 
 
 
Figure 8. The miRNA 
biogenesis pathway. See 
text for explanations (Winter 
et al., 2009, modified). 
 
 
 
For miRNA target recognition, complementarity at miRNA positions 2-7, the ‘seed 
region’, is crucial and evolutionary conserved. Due its brevity (resulting in genomic 
ambiguity) and the nature of imperfect complementarity of the remaining sequence to the 
mRNA, one miRNA has tens to hundreds of mRNA targets119. Further, the functional 
activity of a miRNA in regulating a specific target is context-dependent and cell-type-
specific, as its availability is additionally a function of abundance of alternative targets 
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‘sponging’ miRNA levels, and the affinity of the miRNA for binding to them124-126. One 
mRNA can be bound by multiple miRNAs acting in concert to regulate their target and 
building regulatory networks. miRNAs whose sequence only differs by one or two 
nucleotides (likely to have similar targets) are annotated with an additional lower case 
letter (e.g. miR-320a, miR-320b).  
 
Long non-coding RNAs 
Less than 2% of the human genome encodes for proteins, however, up to 80% is 
actively transcribed127,128. Substantial advances in whole-transcriptome sequencing 
technologies have revealed the widespread transcription of long non-coding RNA 
(lncRNA), which are differentiated from small non-coding RNA (such as miRNA, snoRNA 
(small nucleolar RNA) or piRNA (PIWI-interacting RNA)) by their length of >200 nt. It is a 
very heterogeneous class which is generally poorly conserved129-131. LncRNAs are 
classified according to their position relative to protein coding genes, comprising long 
intergenic ncRNA (lincRNA), intronic lncRNA, antisense lncRNA, transcribed 
pseudogenes and enhancer RNA (eRNA)132. The most recent release from Gencode 
(v19) has annotated ~14 000 human lncRNA genes133. In their biogenesis, lncRNA share 
many characteristics with mRNAs: They are transcribed mostly by RNA polymerase II 
and frequently show polyadenylation134 and 5’-methylguanosine capping135. However, 
they are lowly expressed on average (about 10-fold lower than mRNA) and display a 
higher degree of tissue-specific expression136,137. 
Interestingly, lncRNA have been proposed as a new and potentially crucial layer of gene 
regulation, while the function of the majority of lncRNAs remains unknown138. Through 
their arbitrary definition by sequence length but not functional unity, a great diversity in 
underlying functional mechanisms to regulate gene expression in cis and in trans has 
been described138,139. One of the best-studied examples is Xist (X-inactive specific 
transcript), which was found to be expressed exclusively from the inactive X 
chromosome, and later demonstrated to mediate X chromosome silencing in female 
mammals through chromatin remodeling140,141. It was proposed to act in cis by remaining 
tethered to its site of transcription, affecting neighbouring gene regions – a model 
thought to be valid for a group of lncRNA that e.g. disrupt the transcription machinery by 
DNA binding or foster transcription by attracting transcriptional coactivators138. In 
contrast, others have been described to act in trans by associating with DNA-binding and 
regulatory proteins to guide their localization and affect target gene expression142. This is 
the case for HOTAIR, which functions as a molecular scaffold for histon modifying 
complexes143. However, the mechanisms of lncRNA function are as diverse as the group 
itself, further including disruption of translation, modulation of mRNA stability, masking 
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miRNA binding sites or acting as miRNA ‘sponges’. Some lncRNA have structural 
functions as core components of nuclear bodies such as speckles and paraspeckles138.  
 
1.4.2 Role in human cancer and CLL 
microRNAs 
In 2002, Calin et al. made the seminal observation of frequent deletions and down-
regulation of miR-15 and miR-16 (on 13q14) in CLL, suggesting a role of miRNA 
deregulation in cancer53. Low miR-15 and miR-16 levels have been implicated in CLL 
pathogenesis by increasing the expression of anti-apoptotic Bcl-2 (B-cell lymphoma 2)66.  
It has been shown that aberrant miRNA expression frequently contributes to cancer 
formation through deregulation of cell cycle control, proliferation, apoptosis, 
differentiation, migration and/or epigenetic mechanisms144-149. By targeting mRNA of 
oncogenes or tumor suppressor genes, miRNAs can function as tumor suppressors or 
oncogenes themselves. The oncogenic miR-17~92 cluster serves as prominent example, 
in which individual miRNAs target tumor suppressive members of the Bcl-2 family in 
acute lymphoblastic leukemia150. In CLL, a downregulation of miR-29 and miR-181 
targeting oncogenic TCL-1 is suggested to contribute to pathogenesis151.  
Aberrant miRNA function and regulation can originate from sequence variations in 
miRNA genes, from aberrant transcription mediated by epigenetic mechanisms152-154 as 
reported in gastric and colorectal cancer155,156 from deregulated transcription factor 
activity or from impaired function of the miRNA processing machinery (e.g. Drosha, 
Dicer) as reported also in CLL157-159.  
Characteristic miRNA expression profiles may be exploited for early tumor detection, 
classification and prognosis160-162. This is particularly interesting in solid cancers that are 
difficult to access but display characteristic miRNA expression changes in the peripheral 
blood, as in pancreatic and lung cancer163,164. The remarkable stability of miRNAs in 
biological samples owed to relative resistance to ribonuclease degradation additionally 
renders them to be promising biomarkers165. In CLL, the expression of a set of miRNAs 
associates with prognosis and progression166-168. 
First miRNA-based therapeutics are in clinical development, primarily as replacement 
therapies to reintroduce miRNAs that are downregulated or lost in cancer cells122. Here, 
p53 downstream target miR-34a, itself a tumor suppressor downregulated in 
del17p/TP53mut (and) high-risk CLL70,116,169,170 and a broad range of other 
malignancies171, was the first miRNA mimic to reach phase I clinical trials in 2013 
(clinicaltrials.gov identifier NCT01829971)171,172.  
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Long non-coding RNAs 
There is increasing evidence for a crucial role of lncRNA deregulation in human diseases 
including cancer173-176. One of their major roles is to guide the site specificity of 
chromatin-modifying complexes, impacting on epigenetics. In this context, HOTAIR 
overexpression was shown to greatly influence gene expression to promoting 
invasiveness and metastasis formation in epithelial cancer cells through retargeting of 
chromatin structure remodeling polycomb proteins174. Xist has been found a potent 
suppressor of hematologic cancer in mice, as Xist loss resulted in X reactivation and 
genome-wide, cancer-promoting changes177. As a component of the RNA processing 
machinery controlling alternative pre-mRNA splicing, lncRNA MALAT1 was found 
overexpressed in various cancers176 and linked to an increase in proliferation and 
migration in lung178 and colorectal cancer179. Other lncRNAs have been described as key 
regulators of signaling pathways underlying carcinogesis such as the p53 pathway, as 
detailed in section 1.4.3.  
In CLL, an altered expression profile of transcribed ultraconserved regions (T-UCR) has 
been reported180 and lncRNA BIC (B-cell integration cluster) comprising oncogenic miR-
155 was found overexpressed181. Further, the lncRNA genes DLEU1 (deleted in 
leukemia) and DLEU2 span the minimally deleted region of 13q14182. DLEU1 and 2 have 
been suggested to act on miR-15a/miR-16-1 transcription in cis, eventually 
downregulating NF-kB levels183 and supporting tumor cell survival. A comprehensive 
understanding of the role of lncRNAs in CLL is lacking. 
LncRNA expression is useful for refinement of diagnosis and prognostication in some 
cancers184,185, whereas the exploitation of lncRNAs as therapeutic agents is still in its 
very beginning186. 
  
1.4.3 miRNAs and lncRNAs displaying BCR- or p53-dependent regulation 
in CLL  
microRNAs 
Whereas numerous studies associated miRNA expression profiles to CLL IGHV mutation 
status169,187-189, direct BCR signaling-dependent miRNA expression has been reported 
only once. Upon BCR activation with anti-IgM in vitro and microarray-based 
quantification of miRNA expression changes, Pede et al. found the miR-132/miR-212 
cluster, miR-155-3p, miR-20a-3p and miR-19b-1-5p induced190. However, miRNA 
identification was confined to the sequences on the array, and anti-IgM sets an 
unphysiological trigger to the pathway. Further, no direct connection to tumor cell 
survival or proliferation was drawn, as the targets of those miRNAs in the investigated 
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setting remained undetermined. Of note, in no other B-cell malignancies, a systematic 
screen for BCR signaling dependently expressed miRNAs has been performed. 
The only established miRNA transcriptionally targeted by p53 in CLL is miR-34a-
5p70,116,169,170,191. DNA-damaging irradiation has been shown to induce its expression116. 
miR-34 has been originally characterized as a p53 target in lung, colon and epithelial 
ovarian cancer cells as well as fibroblasts by several groups in parallel192-196. It inhibits 
cell-cycle progression by targeting cyclin-dependent kinases 4163, and 6192,197, cyclin 
D1197 and transcription factor E2F3197,198, and promotes apoptosis by targeting anti-
apoptotic BCL2196 and survivin199. No systematic screen for (further) p53 targets in CLL 
has been reported. In other tumor cells though, numerous p53-regulated miRNAs have 
been identified such as miR-107200, miR-145201 and miR-182193. On the other hand, 
miRNAs including miR-504 were described to target p53202. However, most miRNAs 
reported to target or be targeted by p53 greatly vary between entities and may be 
irrelevant for CLL.  
 
Long non-coding RNAs 
So far, the role of lncRNAs in BCR signaling remains unknown, and p53-dependent 
lncRNAs in CLL cells have not been investigated. 
In contrast, several p53-dependent lncRNAs have been established in other entities 
(Figure 9). The lincRNAs PANDA (p21 associated ncRNA DNA damage activated) and 
lincRNA-p21 are located ~5 kb and ~15 kb upstream of the p21 transcription start site, 
respectively, but expressed independently from p21. Whereas PANDA was shown to 
mediate anti-apoptotic functions of p53 through sequestering transcription factor NF-YA 
away from pro-apoptotic target genes (e.g. Puma, Noxa)203, lincRNA-p21 mediates 
repressive functions of p53 to promote apoptosis upon DNA damage204. In the HeLa cell 
line, lincRNA-p21 was shown to physically associate with JUNB and CTNNB1 mRNAs, 
lowering their translation205. Recent large chromatin immunoprecipitation (ChIP)-based 
sequencing screens for p53 targets in cell lines provide a basis for the identification and 
functional characterization of novel p53-dependent lncRNAs206-209.  
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Figure 9. Long non-coding RNAs as 
regulators and targets of p53.  
A set of lncRNAs has been functionally 
characterized as p53 targets. See text for 
details. The direct regulation of GAS5 by p53 
is being discussed. MEG3, maternally 
expressed 3; TUG1, taurine upregulated gene 
1; GAS5, growth arrest-specific 5, eRNAs, 
enhancer RNAs142,210,211. 
 
 
1.5  Aims of this work 
The role of non-coding RNAs in promoting CLL cell survival and resistance to apoptosis 
remains poorly understood. Active B-cell receptor (BCR) signaling strongly supports B-
cell survival and is upregulated in CLL. The tumor suppressive p53 pathway is a key 
mediator of apoptosis and frequently hit by genomic aberrations, which confer a 
particularly poor prognosis to CLL patients.  
This work set out to identify 1) BCR and 2) p53 signaling-dependent microRNAs and 
further non-coding RNAs in primary CLL by a comprehensive next-generation small RNA 
sequencing-based screen. Pharmacologic inhibitors and the impaired transcriptional 
activity of mutant p53 in primary CLL cells were used to define novel ncRNA targets of 
both pathways.  
The results of this work provide insight into the involvement of miRNAs in promoting 
primary CLL cell survival upon BCR signaling. Moreover, an overview of p53-regulated 
miRNA expression and the identification of novel p53-dependent long ncRNAs shall 
provide a better understanding of (the effects of) impaired p53 activity in CLL and 
potentially across cancer. In a translational sense, this work can pave the way to targets 
for novel, ncRNA-based therapeutic approaches.  
 
  
p53
 lincRNA-p21
 PANDA
 LOC285194
 lincRNA-RoR
 p53 eRNAs
 TUG1
 GAS5 (?) 
MEG3 MALAT1
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2 Material and Methods 
2.1 Material 
2.1.1 Chemicals and Biochemicals 
Reagent Supplier 
2-Propanol Sigma-Aldrich, St. Louis, USA 
Agarose, ultra-pure (Invitrogen) Thermo Fisher Scientific, Waltham, USA 
Annexin V 10x binding buffer Becton Dickinson, Franklin Lakes, USA 
Annexin V- APC Becton Dickinson, Franklin Lakes, USA 
Benzonase VWR, Radnor, USA 
CellTiter-Glo®  Promega, Madison, WI, USA 
Chloroform Carl Roth, Karlsruhe, Germany 
DMSO Sigma-Aldrich, St. Louis, USA 
DNA ladder 50bp, 100 bp (Invitrogen) Thermo Fisher Scientific, Waltham, USA 
DNase I Roche, Mannheim 
Ethanol Sigma-Aldrich, St. Louis, USA 
Ethidium Bromide Applichem, Darmstadt, Germany 
Glycogen Thermo Fisher Scientific, Waltham, USA 
Ficoll-Paque Premium VWR, Radnor, USA 
Ibrutinib (PCI-32765) Selleckchem, Munich, Germany 
Laemmli buffer, 2x concentrate VWR, Radnor, USA 
Loading Dye, 5x Thermo Fisher Scientific, Waltham, USA 
LS columns Miltenyi, Bergisch Gladbach, Germany 
MACS BSA Stock Solution Miltenyi, Bergisch Gladbach, Germany 
MACS Rinsing Solution Miltenyi, Bergisch Gladbach, Germany 
Methanol Sigma-Aldrich, St. Louis, USA 
Milk powder Carl Roth, Karlsruhe, Germany 
Mouse serum Agilent Technologies, Santa Clara, USA 
Nutlin-3 Absource Diagnostics, Munich,  
 Germany  
PageRuler Prestained Protein Ladder  Thermo Fisher Scientific, Waltham, USA 
(Fermentas)  
Phosphate buffered saline (PBS) (Invitrogen) Thermo Fisher Scientific, Waltham, USA 
PhosSTOP Roche, Basel, Switzerland 
Power SYBR Green PCR Master Mix Thermo Fisher Scientific, Waltham, USA 
Propidium Iodide Sigma-Aldrich, St. Louis, USA 
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RNase away Thermo Fisher Scientific, Waltham, USA 
RNase-free water (Ambion) Thermo Fisher Scientific, Waltham, USA 
Sodium Acetate, 3 M, pH 5.2 Sigma-Aldrich, St. Louis, USA 
SYBR® Gold Nucleic Acid Gel Stain Thermo Fisher Scientific, Waltham, USA 
TAE running buffer 1.2 M, 40x Serva Electrophoresis, Heidelberg,  
 Germany 
TaqMan Universal PCR Master Mix II, no  Thermo Fisher Scientific, Waltham, USA 
UNG  
Trizol (Invitrogen) Thermo Fisher Scientific, Waltham, USA 
Western Lightning® Plus-ECL, Enhanced  PerkinElmer, Waltham, USA 
Chemiluminescence Substrate  
 
2.1.2 Consumables 
Consumable Supplier 
Sealing film for PCR plates Steinbrenner, Wiesenbach, Germany 
Sealing film for qPCR plates Roche, Basel, Switzerland 
Cell culture flasks, T25, T75 EasyFlask Thermo Fisher Scientific, Waltham, USA 
Cell culture plates, 6-well, 12-well Greiner BioOne, Kremsmünster, Austria 
Conical tubes 15 ml, Falcon® VWR, Radnor, USA 
Conical tubes 50 ml, Falcon® VWR, Radnor, USA 
Cryo vials, system 100, PP, 2ml VWR, Radnor, USA 
Cryo-Babies® Diversified Biotech, Dedham, USA 
Eptips LoRetention, PCR-clean Neolab, Heidelberg, Germany 
FACS Tubes, BD™ Falcon™ Round-Bottom 
Tube (5ml) 
Becton, Dickinson and Company, 
Franklin Lakes, USA 
FasRead102 Disposable counting chambers Immune systems, Paignton, UK 
Filtertips 10µl, 20µl, 200µl, 1000µl Starlab, Hamburg, Germany 
Gel breaker tubes 3388-100 IST Engineering, Milpitas, USA 
Leucosep falcons, sterile Th. Geyer, Renningen, Germany 
Mini-PROTEAN-TGX gels 4-15%, 10-well Bio-Rad, Hercules, USA 
Novex® Hi-Density TBE Sample Buffer, 5x  Thermo Fisher Scientific, Waltham, USA 
(Invitrogen)  
Novex® TBE PAGE gel, 1.0 mm, 6%  Thermo Fisher Scientific, Waltham, USA 
(Invitrogen)  
Novex® TBE running buffer, 5x (Invitrogen) Thermo Fisher Scientific, Waltham, USA 
Pasteur pipettes, disposable Carl Roth, Karlsruhe, Germany 
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PCR tube strips 0,5 ml Biozym, Hessisch Oldendorf, Germany 
PCR tubes 0,5 ml Biozym, Hessisch Oldendorf, Germany 
Pipettes 2ml, 5ml, 10ml, 25ml, 50ml Corning, New York, USA 
Pipetting reservoir Corning, New York, USA 
Cryotube-print labels Steinbrenner, Wiesenbach, Germany 
Qubit assay tubes Thermo Fisher Scientific, Waltham, USA 
Reaction plates for PCR, 96-well Greiner BioOne, Kremsmünster, Austria 
Reaction plates for qPCR, 384-well Roche, Basel, Switzerland 
Reaction plates for qPCR, 96-well Greiner BioOne, Kremsmünster, Austria 
Reaction tubes 0,5 ml, 1,5 ml, 2 ml Eppendorf, Hamburg, Germany 
Ribbon cartrige  Steinbrenner, Wiesenbach, Germany 
Scalpel, disposable Feather, Osaka, Japan 
Scepter sensors - 40 µl Merck Millipore, Billerica, USA 
Spin-X® Centrifuge Tube Filters Sigma-Aldrich, St. Louis, USA 
Trans-Blot® TurboTM mini-size transfer  Bio-Rad, Hercules, USA 
stacks  
PVDF membrane Bio-Rad, Hercules, USA 
Scepter sensors 40µm Merck Millipore, Billerica, USA 
 
2.1.3 Antibodies 
Antibody Supplier 
Anti-mouse IgG (HRP) Abcam, Cambridge, UK 
Anti-rabbit IgG (HRP) Abcam, Cambridge, UK 
CD19-beads Miltenyi, Bergisch Gladbach, Germany 
CD19-PE Becton, Dickinson and Company, 
Franklin Lakes, USA 
GAM-RPE Agilent Technologies, Santa Clara, USA 
Mouse anti-human p53, DO-1 Becton, Dickinson and Company, 
Franklin Lakes, USA 
Rabbit anti-human GAPDH Abcam, Cambridge, UK 
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2.1.4 Primers for qRT-PCR  
All oligonucleotides were ordered from Eurofins MWG Operon, Ebersberg. 
Gene 5’ → 3’ Reference 
p21 forward (fwd) TGTCCGTCAGAACCCATGC own design 
 p21 reverse (rev) AAAGTCGAAGTTCCATCGCTC 
Lamin B1 fwd TCGCAAAAGC ATGTATGAAGA Sun et al.212 
Lamin B1 rev CTCTACCAAGCGCGTTTCA 
lincRNA-p21 fwd GGGTGGCTCACTCTTCTGGC Huarte et al.204 
lincRNA-p21 rev TGGCCTTGCCCGGGCTTGTC 
NEAT1 fwd CTTCCTCCCTTTAACTTATCCATTCAC Zhang et al.213 
NEAT1 rev CTCTTCCTCCACCATTACCAACAATAC 
NEAT1 promoter fwd GGAGATACAGTCAGGAAGAGA own design 
NEAT1 promoter rev CACAGAAGGTGGTGATGTG 
p21 promoter fwd CTGGACTGGGCACTCTTGTC Mattia et al.214 
p21 promoter rev CTCCTACCATCCCCTTCCTC 
  
Reagent Supplier 
TaqMan® small RNA assays (Applied 
Biosystems) 
Thermo Fisher Scientific, Waltham, USA 
 
2.1.5 Commercial Kits 
Kit Supplier 
DNA 1000 Kit Agilent, Santa Clara, USA 
High Sensitivity DNA Kit Agilent, Santa Clara, USA 
NEBNext® Multiplex Oligos for Illumina New England Biolabs, Ipswich, USA 
NEBNext® Small RNA Library Prep Set for 
Illumina 
New England Biolabs, Ipswich, USA 
Pierce BCA Protein Assay Kit Thermo Scientific, Waltham, USA 
QIAquick® PCR Purification Kit Qiagen, Venlo, Netherlands 
Quant-iTTM RNA Assay Kit (Invitrogen) Thermo Scientific, Waltham, USA 
RNA 6000 Nano Kit Agilent, Santa Clara, USA 
SuperScript® III Reverse Transcriptase 
Super Mix 
Thermo Scientific, Waltham, USA 
TURBO DNA-free™ Kit (Ambion) Thermo Scientific, Waltham, USA 
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2.1.6 Primary human material 
Peripheral blood from 72 patients selected for having high lymphocyte fractions (more 
than 76%) and fulfilling standard diagnostic criteria for CLL were obtained. The majority 
of patients was enrolled at the University Hospital of Heidelberg. RNA derived from 
peripheral blood mononuclear cells of 13 CLL patients used as part of the validation 
cohort for p53-dependent lincRNA-p21 induction (section 3.5.4.1) was kindly supplied by 
the European Research Initiative on CLL (ERIC). All patients provided written informed 
consent in accordance with the Declaration of Helsinki and approval obtained from the 
local Institutional Review Board (S-206/2011 and Te Raa et al.215). The patient cohort 
was selected to represent meaningful numbers of patients from high-risk groups. Clinical 
and genetic patient characteristics are summarized in Table 3 and S1. Buffy coats from 
two healthy individuals were obtained from the Heidelberg Blood Bank.  
 
2.1.7 Cell lines 
Cell line Supplier 
BL-2 DSMZ, Braunschweig, Germany 
BL-7 Dr. G. M. Lenoir, IARC, Lyon, France 
BL-60 Dr. G. M. Lenoir, IARC, Lyon, France 
BJAB DSMZ, Braunschweig, Germany 
CA-46 DSMZ, Braunschweig, Germany 
Cheptanges A. Rickinson, Birmingham, UK 
HeLa DSMZ, Braunschweig, Germany 
Ly-47 Dr. G. M. Lenoir, IARC, Lyon, France 
Namalwa DSMZ, Braunschweig, Germany 
Ramos DSMZ, Braunschweig, Germany 
Salina A. Rickinson, Birmingham, UK 
Seraphine A. Rickinson, Birmingham, UK 
 
Cell lines were authenticated using Multiplex Cell Authentication by Multiplexion 
(Heidelberg, Germany) as described216. The single nucleotide polymosphism profiles 
matched known profiles or were unique. 
 
2.1.8 Cell culture media and additives 
Material Supplier 
Fetal Bovine Serum (for washing) PAN-Biotech, Aidenbach, Germany 
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2.1.9 Self-prepared Buffers  
 
2.1.10 Instruments 
Instrument Supplier 
-20°C Freezer Liebherr, Biberach an der Riß, Germany  
-80°C Freezer Sanyo (Panasonic), Osaka, Japan 
Analytical Balance TE 124S Sartorius, Göttingen, Germany 
Bioanalyzer 2100 Agilent, Santa Clara, USA 
Camera Lumix DMC-FZ50 Panasonic, Osaka, Japan 
Cell culture hood HeraSafe Thermo Scientific, Waltham, USA 
Cell culture incubator HeraCell 150  Thermo Scientific, Waltham, USA 
Centrifuge 5424 Eppendorf, Hamburg, Germany 
Centrifuge 5430 Eppendorf, Hamburg, Germany 
Centrifuge Heraeus Fresco 17  Thermo Scientific, Waltham, USA 
Centrifuge Heraeus Megafuge 16 Thermo Scientific, Waltham, USA 
ChemiDocTM XRS+ Imaging System Bio-Rad, Hercules, USA 
Fetal Bovine Serum (for cell culture) Life Technologies, Carlsbad, USA 
Human Serum Sigma-Aldrich, St. Louis, USA 
RPMI Medium 1640 (Gibco) Thermo Scientific, Waltham, USA 
Buffer Composition  
(final concentration) 
Supplier 
10x PBST buffer 
(phosphate 
buffered saline with 
Tween 20) 
27 mM KCl 
1.37 M NaCl 
0.5 % Tween 20 
100 mM Na2HPO4 
20mM KH2PO4 
in H2O 
 
Carl Roth, Karlsruhe, Germany 
VWR, Radnor, USA 
Sigma-Aldrich, St. Louis, USA 
Carl Roth, Karlsruhe, Germany 
Carl Roth, Karlsruhe, Germany 
RIPA buffer 150 mM NaCl 
0.5 % Na-Desoxycholate 
1 % Nonidet P-40 
0.1 % SDS 
50 mM Tris pH 7.5      
in H2O 
VWR, Radnor, USA 
Applichem, Darmstadt, Germany 
Applichem, Darmstadt, Germany 
Bio-Rad, Hercules, USA 
Applichem, Darmstadt, Germany 
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Chip Priming Station Agilent, Santa Clara, USA 
Cluster Station Illumina, San Diego, USA 
Cobas z 480 Roche, Basel, Switzerland 
Cryogenic Freezer MVE 1500 series MVE BioMedical, Ball Ground, USA 
Electrophoreses Power Supply 200/2000 Elchrom Scientific, Cham, Switzerland 
Eppi Rotator SB3 Bibby Scientific (Stuart), Stone, UK 
Flow Cytometer LSR II Becton, Dickinson and Company,  
 Franklin Lakes, USA 
Fridge Medline Liebherr, Biberach an der Riß, Germany 
Heating block TS-100 Peqlab, VWR, Radnor, USA 
HiSeq2000 Illumina, San Diego, USA 
Infinite M200 Pro® TECAN, Männedorf, Switzerland 
LabChip® XT Perkin Elmer, Waltham, USA 
Label printer BMP71 Brady, Milwaukee, USA 
LightCycler 480 384-well Roche, Basel, Switzerland 
Microscope Axiovert 40C Zeiss, Oberkochen, Germany 
Microwave Bartscher, Salzkotten, Germany 
Minishaker MS1 IKA, Staufen, Germany 
NanoDrop® Spectrophotometer ND-1000 Peqlab, VWR, Radnor, USA 
Nitrogen System German-Cryo, Jüchen, Germany 
PAGE chambers Bio-Rad, Hercules, USA 
Pipetboy Peqlab, VWR, Radnor, USA 
Pipetboy acu Integra Biosciences, Fernwald, Germany 
Pipettes Research® (10μl; 20μl; 200μl;  Eppendorf, Hamburg, Germany 
1000μl)  
QuadroMACS separator Miltenyi, Bergisch Gladbach, Germany 
Qubit® 2.0 Fluorometer Thermo Fisher Scientific, Waltham, USA 
Scepter Handheld automated cell counter Merck Millipore, Billerica, USA 
SDS-PAGE chambers  Peqlab, VWR, Radnor, USA 
SpeedVac Thermo Fisher Scientific, Waltham, USA 
Spin-down Galaxy Mini VWR, Radnor, USA 
TC10™ Automated Cell Counter Bio-Rad, Hercules, USA 
Thermocycler Biometra, Göttingen, Germany 
Transilluminator Biotec-Fischer, Reiskirchen, Germany 
Trans-Blot Turbo Transfer System Bio-Rad, Hercules, USA 
Water bath Lauda®AL5 VWR, Radnor, USA 
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XRAD 320  Precision X-ray, North Branford, USA  
  
2.1.11 Software 
Software Supplier 
Agilent 2100 Bioanalyzer Agilent, Santa Clara, USA 
Axiovision Rel. 4.8 Zeiss, Oberkochen, Germany 
Endnote Thomson Reuters, New York, USA 
FACS Diva Becton, Dickinson and Company,  
 Franklin Lakes, USA 
GraphPad Prism 5 GraphPad Software Inc., La Jolla, USA 
Image Lab 3.0 Bio-Rad, Hercules, USA 
Ingenuity® Qiagen, Redwood City, USA 
Lasergene 8 DNAStar, Madison, USA 
Light Cycler 480 SW 1.5 Roche, Basel, Switzerland 
Microsoft Office 2007 Microsoft, Redmond, USA 
NanoDrop® ND-1000 V3.2.1 Coleman Technologies, Langley, Canada  
Photoshop CS5.1 Adobe, San Jose, USA 
R 3.0.1 open source 
STG Picture Merge Starglider Systems 
Tecan i-control 1.6 TECAN, Männedorf, Switzerland 
 
2.1.12 Databases and online tools 
Name Address 
BLAST (NCBI) http://blast.ncbi.nlm.nih.gov/Blast.cgi 
Ensembl http://www.ensembl.org/index.html 
GtRNAdb http://gtrnadb.ucsc.edu/ 
IDT PrimerQuest http://eu.idtdna.com/Primerquest/Home/Index 
miRBase http://mirbase.org/ 
miRanda http://www.microrna.org/microrna/home.do 
miRwalk http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/ 
PicTar5 http://pictar.mdc-berlin.de/ 
piRNA cluster - database http://www.uni- 
 mainz.de/FB/Biologie/Anthropologie/492_DEU_HTML.php 
NCBI Build 37 piRNA http://www.uni-mainz.de/FB/Biologie/Anthropologie/ 
 492_DEU_HTML.php 
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Primer3Plus http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus. 
 cgi/ 
Rfam http://rfam.xfam.org/ 
SNP-BLAST www.ncbi.nlm.nih.gov/projects/SNP/SNPBlast.html 
TarBase http://diana.imis.athena- 
 innovation.gr/DianaTools/index.php?r=tarbase/index 
UCSC Genome Browser https://genome.ucsc.edu/ 
 
2.1.13 Other 
Material Supplier 
Freezing Boxes Nalgene, Rochester, USA 
Western incubation box (medium) Li-cor, Lincoln, USA 
 
2.2 Cell culture methods 
2.2.1 Isolation of mononuclear cells from whole blood 
Peripheral blood (PB) samples from CLL patients were collected in heparin-coated 
tubes. Mononuclear cells (MNCs) were isolated by density gradient centrifugation of 30 
ml whole blood over 15 ml Ficoll-Paque Premium at 800x g, room temperature (RT) for 
20 min in 50 ml Falcon tubes. The resulting PBMNC layer was harvested and washed 
twice with PBS supplemented with 2% FBS. PMNCs were resuspended in RPMI 
containing 10% FBS for further processing.  
 
2.2.2 Magnetic activated cell sorting (MACS) 
For enrichment of B-lymphocytes from peripheral blood mononuclear cells (PBMNCs) of 
healthy individuals, activated cell sorting with CD19 magnetic beads was performed 
according to the manufacturer´s protocol. To this end, after cell counting and 
centrifugation, cells were resuspended in 80 μl MACS buffer per 1x107 PBMCs. 20 μl 
magnetic beads were added, followed by a 15 min incubation at 4°C in the dark. After a 
subsequent washing step, cells were purified on MACS LS columns during exposure to a 
strong magnetic field. To increase purity, B-cells were purified sequentially over 2 
columns.  
CD19 positive-selected B-cells were stained with a secondary goat anti-mouse antibody 
for subsequent FACS analyses (see 2.2.5). The cells had purities of at least 99% after 
MACS enrichment. 
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2.2.3 Freezing, thawing and culturing of primary cells and cell lines 
Isolated PBMNCs were split into aliquots of 1x107-5x108 cells and cryopreserved in 
RPMI supplemented with 10% FBS, 1% Penicilline/Streptomycine and 7,5% DMSO.  
Cell lines were cryopreserved at 5x106-1x107 cells per aliquot in RPMI supplemented 
with 10% FBS and 10% DMSO. 
For culturing, cells were thawed in a waterbath pre-warmed to 37°C, transferred to PBS 
with 2% FBS for washing and resuspended in the desired cell culture medium.  
CLL primary samples were cultured in RPMI 1640 supplemented with 10% heat 
inactivated human serum (HS) at 37°C and 5% CO2. Only for the pilot small RNA 
sequencing screen, cells were cultured in 10% FBS instead of HS. With the exception of 
BL-7, all Burkitt’s lymphoma (BL) cell lines as well as HeLa were kept in RPMI 1640 with 
10% FBS at 37°C and 5% CO2. BL-7 was cultured with 20% FBS. A list of the cell lines 
used as well as their TP53 status is provided in table S2. 
 
2.2.4 Cell culture treatments 
For experiments with CLL primary cells, the cryopreserved samples were thawed, 
adjusted to 107 cells/ml and allowed to equilibrate for 30 min at 37°C and 5% CO2.  
For induction of DNA damage and p53, CLL samples were subjected to 5 Gy irradiation 
(IR) or treated with 1 µM, 5 µM or 10 µM nutlin-3 (10 mM stock in DMSO) and harvested 
after 24h. Untreated controls or, for nutlin-3 experiments, cells incubated with the 
corresponding DMSO concentration (0.01-0.1%) incubated for the same time period 
were included. At harvest, aliquots of every sample were prepared for viability analysis in 
FACS. The remainder was pelleted and lyzed in Trizol®.  
For inhibition of BCR signaling at the level of BTK, CLL cells were induced with 1 µM 
ibrutinib (1 mM stock in DMSO) or left untreated for 24h and harvested thereafter as 
above. 
Cell lines were seeded at 106 cells/ml, IR with 5 Gy, harvested 6h, 12h, and 24h 
thereafter, pelleted and flash-frozen in liquid nitrogen or treated with 0, 2.5 or 10 µM 
nutlin-3 and harvested likewise after 24h. Untreated or solvent-treated controls were 
included.  
 
2.2.5 Fluorescence activated cell sorting (FACS) 
Viability staining of CLL samples  
To quantify apoptotic cells, double-staining with Annexin V-allophycocyanin (APC) and 
propidium iodide (PI) was performed. To this end, 1x105 cells were washed in 200 µl 
PBS with 2% FBS and resuspended in 100 µl cold 1x Annexin V binding buffer. For each 
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sample, one aliquot was left unstained as control. To another aliquot, 2 µl Annexin V-
APC and 2 µl PI (1:50 diluted in PBS) were added for a 15 min incubation at 4°C in the 
dark. Subsequently, 400 µl cold 1x Annexin V binding buffer were added and the 
samples were analysed on a BD LSR II FACS using the FACS Diva software. 10 000 
events were recorded. 
 
Staining of B-cells after MACS 
To check the B-cell purity of samples after MACS, 1x105 cells of the resulting B-cell 
fraction were washed in 200 µl PBS with 2%FBS and resuspended in 100 µl PBS with 
2% FBS. For staining of CD19, 1 µl R-phycoerythrin (RPE)-coupled goat anti-mouse 
(GAM) antibody was added. Unstained samples were included as control. After 20 min 
incubation at RT in the dark, PBS with 2% FBS was added to the GAM-stained samples 
for washing. The pellet was resuspended with 10 µl mouse serum and incubated for 10 
min at RT. It was then again washed with PBS and 2% FBS and resuspended in 300 µl 
PBS with 2% FBS for analysis on a BD LSR II FACS using the FACS Diva software, 
recording 10 000 events. 
 
2.4.6 Cell viability assessment using CellTiter-Glo® 
For screening sensitivity to ibrutinib treatment in vitro, cryopreserved PBMNC samples 
were thawed, seeded in 384 well plates at a density of 10 000 cells in 50 µl RPMI 1640 
supplemented with 10% heat inactivated human serum per well. Cells were incubated 
with ibrutinib at 1 µM for 48 hours. Cell viability was assessed using CellTiter-Glo® assay 
according to the manufacturer’s protocol. Data were kindly generated by Leopold 
Sellner. 
 
2.5 Molecular Biology 
2.5.1 RNA isolation  
Total RNA was isolated using Trizol®. In brief, up to 107 cells were lyzed in 1 ml Trizol® 
and frozen at -80°C. For isolation, the lysate was allowed to adjust to room temperature 
for 5 min and extracted with 200 µl chloroform. For all further procedures, the RNA 
containing solution was kept on ice or at 4°C. After spinning at 12 000g and 4°C for 15 
min, the resulting aqueous supernatant was precipitated with an equal volume of 
isopropanol and 10 µg glycogen at -20°C for 30 min. The precipitate was pelleted, 
washed with ice-cold 75% ethanol and allowed to air-dry. It was then dissolved in the 
desired volume of RNase-free water. 
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For purification of RNA from DNA contaminants, DNA digestion was performed with the 
TURBO DNA-free™ Kit following the manufacturer’s instructions for routine DNase 
treatment. Up to 10 µg RNA were processed in one 50 µl reaction. After DNA digestion, 
RNA was purified from the kit’s buffer by precipitation with an equal volume of 
isopropanol and 10 µg glycogen as described above. The RNA pellet was washed, dried 
and dissolved in RNase-free water. The RNA concentration and purity was determined 
on the NanoDrop® ND-100 spectrophotometer. The RNA solution was then aliquoted to 
avoid repeated freeze-thaw cycles, and stored at -80°C. 
At the start of this project, a large batch of HeLa cells was cultured, harvested and RNA 
was extracted, pooled, aliquoted and stored at -80°C to serve as reference throughout all 
qRT-PCR experiments. 
 
2.5.2 RNA quantification and quality control 
Quantification and a first quality control of isolated RNA was performed on a 
NanoDrop®. The RNA concentration was determined from the absorption of 1 µl sample 
at 260 nm, the absorption maximum of nucleic acids. Additionally, the absorption at 230 
nm and 280 nm was used to estimate the extent of contamination with phenol and 
protein (at 280 nm) or phenol and carbohydrates (at 230 nm).  
As ubiquitous RNases quickly and easily degrade RNA, using RNA of high integrity is 
vital to obtain meaningful experimental results. RNA integrity of all samples prepared for 
small RNA sequencing was determined on a 2100 Bioanalyzer using the RNA 6000 
Nano Kit according to the manufacturer’s instructions. Here, stained RNA is 
electrophoretically separated based on size and the RNA integrity number (RIN) is 
calculated considering primarily the intensity and ratio of signals corresponding to 18S 
and 28S ribosomal RNA.  
With two exceptions, only samples with a RIN of ≥ 7 were used for small RNA library 
preparation. 
2.5.3 cDNA synthesis (reverse transcription) 
cDNA synthesis for miRNA quantification 
To determine the relative amount of miRNA expression, TaqMan Small RNA Assays 
containing target specific primer and probe sets for cDNA synthesis and quantitative 
real-time PCR (qRT-PCR) were used according to the manufacturer’s instructions. The 
expression of RNU6B was used for normalization. Assay volumes were down-scaled by 
50% for quantification of all miRNAs and RNU6B except for quantification of miR-34a-5p. 
Therefore, cDNA was synthesized from 5 or 10 ng RNA per sample in target specific 7,5 
or 15 µl reactions. 
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cDNA synthesis for mRNA/lncRNA quantification 
For long RNAs, cDNA was prepared from 120-500 ng RNA per sample using the 
SuperScript III First-Strand Synthesis SuperMix with random hexamer primers according 
to the manufacturer’s instructions. The resulting cDNA was diluted to 5 ng/µl for further 
analyses. 
 
2.5.4 Primer design for qRT-PCR 
qRT-PCR primers for were manually designed following the subsequent criteria: A primer 
length of between 18 and 23 base pairs, a melting temperature preferentially between 
58-65°C with less than 3°C difference between forward and reverse primer and a G/C-
content of about 50-60%. Primers on the target sequence were picked using 
Primer3Plus and IDT PrimerQuest. Generation of hairpin structures and primer dimers 
was minimized using binding prediction tools of DNAStar Lasergene 8. To ensure gene 
specificity, primer sequences were run in BLAT and BLAST. To additionally ensure the 
absence of single-nucleotide polymorphisms (SNPs) within the primer sequence, SNP-
BLAST was run. Primers were ordered from Eurofins. 
 
2.5.5 Quantitative real-time PCR (qRT-PCR) 
Quantification of miRNA 
Target specific cDNA obtained in 2.5.3 was quantified using TaqMan Small RNA Assays 
following the manufacturer’s protocol. The assays were run in 10 µl or 20 µl reactions in 
triplicates or duplicates, respectively, on 384-well-plates. A HeLa RNA sample was run 
on every plate as additional reference. 
 
Quantification of long RNA transcripts (mRNA, lncRNA, promoter sequences) 
For quantification of p21, NEAT1 and Lamin B1 transcripts, 2 µl of the 5 ng/µl random 
hexamer primed cDNA obtained in 2.5.3 were used per qRT-PCR reaction. They were 
added to a master mix composed of 10 µl SYBR Green, 6 µl H2O, 1µl forward primer (5 
µM) and 1 µl reverse primer (5 µM), resulting in a reaction volume of 20 µl. For lincRNA-
p21 quantification, 6 µl cDNA were used and the water content of the master mix was 
adapted accordingly. The expression of Lamin B1 was chosen for normalization, as it 
was observed to be unaffected by the treatments. A HeLa RNA sample was run on every 
plate as additional reference. qRT-PCR was performed on a LightCycler 480 in 384-well-
plates. The program was run as detailed in Table 2. A melting curve analysis was 
Material and Methods 
32 
 
performed to ensure assay specificity, and only wells displaying target-specific 
amplification were chosen for further analysis. 
For NEAT1, lincRNA-p21 and Lamin B1, the primer annealing temperature was 59°C. 
For p21 and Lamin B1 quantification it was 58°C. 
 
Table 2. qRT-PCR program run for the quantification of lincRNA-p21, NEAT1 and p21.  
Detection 
Format Block Type Reaction Volume         
SYBR Green I 384 20µl           
Programs               
Name Cycles Analysis Mode         
Pre-Incubation 1 None           
Amplification 40 Quantification         
Melting Curve 1 Melting Curve         
Cooling 1 None           
 Programs in detail             
Target (°C) Acquisition Mode 
Hold 
(hh:mm:ss) 
Ramp 
Rate 
(°C/s) 
Acquisi-
tions 
(per°C) 
Sec 
Target 
(°C) 
Step 
Size 
(°C) 
Step 
Delay 
(cycles) 
Pre-Incubation               
95 None 00:10:00 4,4   0 0 0 
Amplification        
95 none 00:00:15 4,4   0 0 0 
variable None 00:01:00 2,2  0 0 0 
72 single 00:00:05 4,4   37 0 0 
Melting Curve        
95 None 00:00:05 4,4         
65 None 00:01:00 2,2      
97 continuous   0,06 10       
Cooling        
40 None 00:00:10 1,5   0,0 0 0 
  
 
2.5.6 Agarose gel electrophoresis 
To additionally ensure target specificity of qRT-PCR assays with SYBR Green, the 
product of the qRT-PCR reactions was run on an agarose gel and checked for the 
correct amplicon size. As amplicons were of 67 – 116 nt length, 3% agarose gels were 
prepared. Agarose was melted in 1x TAE buffer and 1-2 drops ethidium bromide were 
added for nucleic acid visualization. DNA samples were mixed 1:5 with 5x loading dye 
and loaded onto the gel; a 50 or 100 bp DNA ladder was included in every run. The gel 
was run at 120 V for 75 min and subsequently analyzed on a transilluminator. 
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2.5.7 Small RNA library preparation 
For next-generation sequencing, 1 µg total RNA/sample was converted into a barcoded 
cDNA library using the NEBNext® Small RNA Library Prep Set for Illumina according to 
manufacturer’s instructions with the following specifications/adaptations: 
• After ligation of the 5’ SR Adaptor, 18 µl H2O were added to the 30 µl total 
volume, and half of the reaction volume was stored at -20°C as backup. The 
other half was further processed for sequencing. 
• During size selection of the amplified cDNA library on a polyacrylamide gel, 
bands corresponding to nucleic acids of approximately 15 - 35 nt length were 
selected. This was performed manually for the pilot screen, whereas the 
LabChip® was implemented for the main screen. 
• To recover nucleic acids from the gel, the crushed gel slices were eluted for at 
least 16 h instead of 2 h to increase the yield. 
Library preparation was performed at, and supported by, the DKFZ Genomics and 
Proteomics Core Facility. 
 
2.5.8 Next-generation Sequencing 
Libraries were amplified on an Illumina cBot and sequenced on llumina’s Hiseq 2000 
platform, running 7-9 libraries per lane with 50 bp single read sequencing. Amplification 
and sequencing were performed by the DKFZ Genomics and Proteomics Core Facility. 
 
2.5.9 Protein extraction  
Cell aliquots intended for protein extraction were harvested at 106 cells per aliquot and 
washed once with PBS. Upon removal of all PBS, the cell pellets were snap-frozen in 
liquid nitrogen to disrupt the cell structure and stored at -80°C. For extraction of protein, 
106 cells were resuspended in 20 µl RIPA buffer containing 125 U/ml Benzonase and 1x 
protease/phosphatase inhibitors. The sample was vortexed and kept on ice for 30 min, 
vortexing every 10 min.  
 
2.5.10 Determination of protein concentration 
Protein concentrations were measured using the BCATM Protein Assay Kit according to 
the manufacturer’s instructions. Sample protein solutions were diluted 1:10 for 
measurement, and concentrations were determined in a 96-well format. 
Chemiluminescence was detected on a microplate reader. Protein concentration was 
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adjusted to 2 µg/µl in all samples. Isolated protein was immediately used or stored at -
20°C. 
 
2.5.11 Western Blot 
For Western Blot, protein was first separated according to size by poly-acrylamide gel 
electrophoresis. To this end, pre-cast Mini-PROTEAN-TGX gels 4-15% were placed into 
a Bio-Rad gel chamber, which was subsequently filled with 1x Bio-Rad 
Tris/Glycerine/SDS running buffer. Samples were mixed 1:2 with 2x Laemmli buffer and 
a volume equaling 10 µg protein was inserted into every lane, reserving one lane for the 
marker. Gels were run at 120 V for 70 min. After electrophoresis, the gels were removed 
from the chamber, the stacking gel was separated from the resolution gel, and the latter 
was used for transfer of the proteins onto a PVDF membrane. 
For Western blotting, a Trans-Blot Turbo PVDF-LF membrane cut was activated in 
methanol for 1 min and equilibrated in transfer buffer. Per gel, two stacks of filter paper 
were soaked in transfer buffer. One stack was placed on the lower side of the blotting 
chamber, the membrane was added, then the gel and another soaked filter paper stack. 
Blotting was run at 25 V for 10 min. 
The membrane was then briefly washed in methanol and incubated in blocking buffer (5 
% milk in PBST) for 1 h at room temperature (RT). The membrane was then incubated 
with primary antibody diluted 1:1000 (anti-GAPDH) or 1:5000 (anti-p53) in blocking buffer 
at 4°C over night, or alternatively at RT for 2 h. It was then washed 3x 5 min with PBST 
on a shaker, then secondary horseradish peroxidase-coupled antibody in blocking buffer 
was added according to host species at a dilution of 1:10 000. The membrane was 
incubated for 1 h at RT and washed 3x 5 min with PBST. 1 ml Western Lightning Plus-
ECL Enhanced Luminol Reagent Plus and 1 ml Western Lightning Plus-ECL Oxidizing 
Reagent Plus were mixed, added dropwise onto the membrane and incubated for 5 min 
at RT. Chemiluminescence was detected directly on a ChemiDoc station, capturing 10-
300 s exposure. An additional white light picture of the membrane was taken to record 
the marker bands and later on merged with the chemiluminescence picture.  
 
2.5.12 Chromatin immunoprecipitation (ChIP)-PCR 
107 cells were harvested from the Séraphine p53wt and the isogenic p53ko cell line in 10 
ml cell culture medium. 1% paraformaldehyde was added and incubated for 10 min at 
37°C to crosslink proteins and chromatin. This was terminated by addition of 125 mM 
glycine and incubation for 5 min at RT. Cells were washed with cold PBS containing 
protease inhibitors and aliquoted, as 106 cells were used for each ChIP experiment. 106 
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cells were resuspended in 500 µl lysis buffer from Millipore’s ChIP Assay Kit, and further 
steps were performed according to the manufacturer’s protocol using the following 
specifications and adaptations: Chromatin was sheared to 200 - 400 bp using a Covaris 
S220 sonicator for 5 x 10 min set to duty cycle 20%, intensity 5, 200 cycles per burst, 
60s. Subsequently, shearing was checked on a 1.5% agarose gel. Aliquots were saved 
as input control. No antibody or 2 µg DO-1 p53 antibody (from Santa Cruz Biotechnology 
or BD Biosciences) were added for incubation at 4°C over night. Elution and de-
crosslinking were performed simultaneously, and AMPure SPRI beads were used for 
DNA purification post de-crosslinking according to the manufacturer’s instructions. 
NEAT1 and p21 promoter sequences were detected by qRT-PCR running the program 
detailed in section 2.5.5, using 56°C and 59°C as annealing temperature, respectively, 
and 10 s for elongation at 72°C. Half of the PCR product was subsequently run on a 3% 
agarose gel.   
 
2.6 Bioinformatics and Statistics 
2.6.1 Read processing and mapping 
The sequencing reads obtained were quality filtered, adaptor trimmed, size selected for 
reads of 17-25nt length and bowtie-aligned to the human mature miRNA sequences of 
miRBase v19 requesting perfect sequence identity. Likewise, reads of ≥ 15nt not 
mapping to mature miRNA sequences were bowtie-aligned to human mRNA and ncRNA 
sequences derived from a set of databases (Ensembl 71, GtRNAdb217, Rfam 11.0, 
piRNA cluster database218). For these purposes, pipelines implemented in the HUSAR 
system at DKFZ were used219 with the support of Agnes Hotz-Wagenblatt. Analyses for 
this study did not exclude multiple mapping reads. This was done to include miRNAs 
with high numbers of genomic loci (e.g. miR-1246: on chromosome 2, 3, 5, 6, 13, 14 and 
17; miR-941: 7 loci on chromosome 20) and to avoid losing a large fraction of 
sequencing reads. 
 
2.6.2 Data analysis and statistics 
Mapped raw sequencing read count data were normalized using DESeq2 in R220. Only 
RNAs with an average of ≥ 5 counts across samples or a count of ≥ 10 in at least one of 
the samples were considered for further analysis. Dispersion of each RNA was 
estimated using the Cox-Reid adjusted profile likelihood approach221. The Wald test 
based on the negative-binomial regression model was used to detect differentially 
expressed RNAs, accounting for batch effect and sample pairing in the model. P-values 
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were adjusted for multiplicity using Benjamini-Hochberg correction. Hierarchical 
clustering of log2-transformed fold changes was done using euclidean distance and 
Ward’s linkage. The L1 penalized regression model was implemented for the 
identification of a miRNA signature predicting IGHV status. 
For miRNA target identification, normalized read counts were transformed using 
regularized log-transformation as implemented in the rlogTransformation function in 
DESeq2. The batch effect was removed from the transformed count data using the 
removeBatchEffect function from limma222. Pearson’s correlation coefficient including 
95% confidence interval between transformed miRNA and mRNA expression levels was 
computed and tested using the cor.test function. miRanda118, miRWalk223 and 
TargetScan224 were used to predict miRNA targets. 
All analyses were conducted with R/Bioconductor 3.0.1 and Bioconductor package 
DESeq2 1.0.19221 and greatly supported by Thomas Hielscher. Student’s t-test was 
applied on qRT-PCR data in GraphPad Prism. All tests were two-sided. P-values below 
0.05 were considered statistically significant. 
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3 Results 
 
The activity of BCR signaling and the p53 signaling pathway is of central importance to 
CLL tumor cell survival, hence influences disease progression and patient’s response to 
treatment. To improve our understanding of the involvement of non-coding RNAs in 
these contexts, this work set out to comprehensively identify novel non-coding RNAs 
implicated in BCR signaling or the p53 signaling pathway by applying small RNA 
sequencing. 
 
3.1 Establishment and validation of the small RNA sequencing 
approach  
 
To establish the sequencing and data analysis pipeline for small RNA quantification, first 
a pilot screen was performed on libraries generated from samples of two previously 
untreated TP53wt and three TP53del/mut CLL patients (indicated by green numbers in 
Figure 11). Cells were treated with 5 Gy for p53 induction or left untreated, and 
harvested after 24 hours for RNA isolation. The dataset obtained from small RNA 
sequencing was checked for sufficient read coverage, read length distribution, 
comparability of miRNA expression levels to published datasets, and reproducibility, as 
discussed in the following paragraphs. For all analyses from section 3.2 forward, the 
datasets of pilot and main screen were combined.  
In the pilot screen, an average coverage of 39.8 Mio raw reads/sample (min. 24.3 – max. 
58.6 Mio/sample) were obtained, of which on average 22% perfectly mapped to mature 
miRNA sequences (miRBase v19). Known p53 target miR-34a-5p, serving as positive 
control, was represented by an average of 328 reads per sample at baseline, i.e. after 24 
hours of cell culture without treatment. A dynamic range with a minimum of 15 and a 
maximum of 1169 reads per sample reflected expected inter-patient differences and 
induction after DNA damage as assessed by qRT-PCR for miR-34a-5p. The total and 
miRNA-34a-5p read coverages were higher compared to similar small RNA sequencing 
studies225-227. In conclusion, this sequencing depth should allow sensitive, high-resolution 
profiling of miRNA expression.  
The length of adaptor-trimmed reads ranged from 5 to 45 nucleotides (nt) as exemplified 
in Figure 10A, peaking at 22 nt as expected for mature miRNA sequences. Since the 
length of 99.1% of human miRNAs falls within the range of 17-25 nt (miRBase v19) and 
short, random RNA degradation products were to be excluded, miRNA expression 
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analyses were confined to reads of this length range. Within this selection, on average 
36% of reads mapped to mature miRNA sequences.  
A comparison of the 30 most abundantly expressed miRNAs at baseline to those 
reported by Landgraf et al.227 and Jima et al.225 yielded a good overlap of 22 and 18 
miRNAs, respectively (table S3). 
Sequencing data reproducibility was verified by two approaches: Firstly, by 
independently preparing two small RNA libraries of one sample, which produced nearly 
identical sequencing results (R2 = 0.99, Figure 10B) and secondly, by validating the 
expression of miR-34a-5p and miR-151-5p by qRT-PCR. Figure 10C, D display the 
correlation of expression levels as determined by the two quantification methods across 
all sequenced screen samples, comprising the 5x2 samples of the pilot screen. Strong 
correlations of qRT-PCR and sequencing data were observed (R2 = 0.70 and R2 = 0.76, 
respectively).  
 
 
Figure 10 Establishment and validation of small RNA sequencing. (A) Read length 
distribution for a representative sample, indicating the 17-25 nt selection used for miRNA 
quantification. (B) Correlation of miRNA quantity in two independently prepared libraries of the 
same sample (technical replicates). Every dot represents one miRNA; non-normalized read 
counts are plotted. (C, D) Correlation of miR-34a-5p (n = 83) and miR-151a-5p (n = 73) 
expression, respectively, as quantified by small RNA sequencing (seq) and qRT-PCR. 
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In conclusion, the described miRNA quantification and sequencing data analysis pipeline 
allowed reliable, high-resolution quantification of miRNA, and qualified for application to 
this project’s research question. It was applied to the whole screening approach used to 
identify p53-dependent and BCR signaling dependent ncRNA as delineated in Figure 11.  
 
 
Figure 11. Graphical summary of the screening approach used in this study. The screen 
included peripheral blood mononuclear cells (PBMNCs) of 35 CLL patients and two healthy B-cell 
controls. Samples of the pilot screen (n = 5) are indicated in green. Refer to text for details.  
 
This sample set was generated from cryopreserved peripheral blood mononuclear cells 
(PBMNCs) of 35 CLL patients selected for high tumor load and stratified by p53 status 
and prior therapy for CLL (see Table 3 for clinical and molecular characteristics) as well 
as two pooled CD19 positive selected healthy B-cell controls. It encompassed three 
different treatments in total. p53 induction by 5 Gy irradiation was used for the 
identification of p53-dependent ncRNA transcripts and applied on 34 samples, whereas 
BTK-inhibition by ibrutinib to identify BCR signaling dependent miRNAs was performed 
on 12 samples only; no treatment controls were prepared for all samples. Healthy B-cell 
controls were not taken into culture, but RNA was directly extracted from isolated cells. 
The irradiation dose was chosen according to Zenz et al.116, who at this dose observed a 
strong induction of p53 target miR-34a-5p at 24 h upon treatment of primary CLL cells. A 
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dose of 1 µM ibrutinib had previously been demonstrated to strongly inhibit BCR 
signaling in vitro99,100. At 24 hours post induction, cell viability was monitored by Annexin 
V / propidium iodide staining and flow cytometric analysis (FACS). Total RNA was 
isolated, DNase treated and analyzed by qRT-PCR for the expression of selected targets 
of interest. RNA aliquots of the identical samples were subjected to small RNA library 
preparation and next-generation sequencing on an Illumina HiSeq 2000.  
All further analyses were performed on the combined data of pilot and main screen.  
 
Table 3. Summary of clinical and genetic characteristics of the patient samples screened. 
11 of the 12 patients used for in vitro ibrutinib treatment were part of the irradiation treated sample 
set. 
 Parameter Irradiated Ibrutinib treated 
Clinical 
Number of patients (n) 34 12 
Median age, years (range) 68 (48 - 90) 66 (49 - 77) 
Female gender (%) 44 50 
Median PB leukocytes / nl (range) 89 (27 - 262) 154 (100 - 262) 
Median PB lymphocyte fraction  
(% of leukocytes) (range) 95 (76 - 100) 99 (90 – 100) 
Pretreated, n (%) 17 (50) 6 (50) 
FISH 
13q14 deletion, n (%) 20 (59) 10 (83) 
17p13 deletion, n (%) 10 (29) 5 (42) 
11q23 deletion, n (%) 5 (15)   2 (17) 
Trisomy 12, n (%) 4 (12) 2 (17) 
8q24 amplification, n (%) 3 (9) 1 (8) 
Mutations 
IGHV unmutated (%) 17 (53)* 8 (67) 
TP53 mutation, n (%) 10 (29) 5 (33) 
ATM mutation, n (%) 2 (6) 1 (8) 
SF3B1 mutation, n (%) 7 (21) 1 (8) 
BRAF mutation, n (%) 3 (9) 2 (17) 
NOTCH1 mutation, n (%) 2 (6) 1 (8) 
*= 17 of 32, as IGHV status was unknown for 2 patients. One sample displaying 6% TP53 
mutation (no 17p deletion) was counted as TP53wt, as this low fraction of mutated cells is not 
expected to alter the p53 response. 
 
 
3.2 Induction of known p53 targets after DNA damage in primary CLL 
cells 
Prior to sequencing the main screen samples, apoptosis induction and p53 key target 
expression levels were monitored in PBMNCs of the cohort by qRT-PCR to examine 
whether TP53 status dependent expression would be detected. Of the 34 samples that 
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were treated with 5 Gy irradiation (or left untreated) and harvested 24 hours thereafter, 
19 were p53 wild-type, carrying no genetic abnormalities in the p53 pathway as 
determined by routine FISH (i.e. no TP53 or ATM deletion). Five displayed monoallelic 
deletions of the p53 activating kinase ATM encoded on chromosome 11q22.3 (del11q). 
In 10 samples, monoallelic deletions of chromosome 17p13 (TP53) and / or mutations in 
TP53 had been detected by FISH or 454 sequencing, respectively (for details on sample 
genetics, see also table S1).  
Induction of apoptosis indicative of p53 activation was quantified by staining with 
Annexin V (marking apoptotic cells) and propidium iodide (marking cells with 
damaged/porous plasma membrane, i.e. late apoptotic and necrotic cells) in FACS. The 
expression of p21 and miR-34a-5p, two key p53 transcriptional targets was assessed by 
qRT-PCR.  
After IR-triggered DNA damage induction, only the group of TP53wt samples displayed a 
significant increase in apoptotic cells (total Annexin V positive: NT 32% vs. IR 47% 
(median), p < 0.001), whereas samples displaying genetic aberrations of TP53 or ATM 
were largely resistant to this treatment (del11q: 31% vs. 33%, p = 0.15; TP53del/mut 32% 
vs. 36%, p = 0.91 (median values) (Figure 12 and Figure 13)). 
 
 
Figure 12. Effects of 5 Gy irradiation (IR) on CLL cell apoptosis. TP53wt (n = 19), del11q (n = 5) 
and TP53del/mut (n = 10) samples were analyzed by Annexin V / propidium iodide (PI) staining in 
FACS to quantify apoptosis induction (APC-Annexin positivity). 
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Figure 13. Examples of the impact of 5 Gy irradiation (IR) on cell viability / apoptosis. (A) 
provides a representative example of the impact of IR on cell viability of a TP53wt sample (upper 
panels: NT 34%, lower panels: IR 46% Annexin positive). The increase in the apoptotic cell fraction 
after IR is best appreciated by the drop in viable, double-negative cells. (B) is a representative 
example of effects of IR on cell viability of a TP53del/mut sample (upper panels: NT 27%, lower 
panels: IR 28% Annexin positive cells). SSC, side scatter; FSC, forward scatter. 
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IR
B
NT
IR
Results 
43 
 
Analysis of p53 downstream target expression demonstrated a strong and significant 
induction of p21 expression in TP53wt samples due to IR-triggered DNA damage (relative 
expression median untreated: 1.1 vs. IR: 24.8, p < 0.001), whereas this effect was less 
pronounced in del11q patients (1.3 vs. 7.9, p = 0.17) (Figure 14A). As expected, 
induction was lowest in TP53del/mut samples (1.3 vs. 3.6, p = 0.02). The TP53 genetic 
subgroups could be clearly distinguished by their p21 expression level post IR, which 
was significantly higher in TP53wt than TP53del/mut samples (p < 0.001). This was also true 
for miR-34a-5p expression. Here, markedly higher expression levels in TP53wt than 
TP53del/mut samples were already detected at baseline (15.7 vs. 5.7, p = 0.02) (Figure 
14B). Induction of miR-34a-5p and p21 was still seen in TP53del/mut samples at a low 
level, which is owed to the subclonality of p53 aberrations (26 - 92%) resulting in residual 
p53 activity.  
 
 
Figure 14. Effects of 5 Gy irradiation (IR) on p53 target gene expression. p21 (A,C) and miR-
34a-5p (B,C) expression in the screen samples 24h post +/- 5 Gy IR quantified by qRT-PCR, by 
genetic status of TP53 and ATM (11q). Means and standard deviations are indicated. Target gene 
expression was normalized to RNU6B and referenced to a HeLa sample. 
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While miR-34a-5p and p21 expression levels were not found to correlate in untreated 
samples (R2 = 0.07, data not shown), a strong correlation was observed after IR (R2 = 
0.62, p < 0.001, Figure 14C).  
The results confirmed previous data116,191, and cohort and experimental setup appeared 
suitable for the identification of transcriptional p53 targets.  
Patient treatment status influenced DNA damage-triggered induction levels of p21. 
Samples of patients previously treated for CLL displayed reduced p21 induction 
independent of TP53 status (median fold increase in TP53wt, 11q disomic, untreated 
CLLs (n = 15): 26.4, in TP53wt treated CLLs (n = 9): 6.8, p = 0.001, Figure 15A). This 
was largely independent from ATM status of samples of treated patients, as samples 
with del11q or ATM mutation (n = 6) displayed a 10.0 fold induction, and ATM wild-type, 
disomic ones (n = 3) a 3.8 fold induction (p = 0.28, data not shown). This suggests 
impaired p53 pathway activation in tumor cells of treated CLL patients, which is 
independent of TP53 and ATM status.  
For miR-34a-5p induction, no influence of previous patient treatment was observed (4.7 
fold in samples of TP53wt previously untreated patients vs. 5.9 fold in TP53wt previously 
treated ones) (Figure 15B).  
 
 
Figure 15. DNA damage-triggered p21 and miR-34a-5p induction by patient treatment 
status. . (A) p21 and (B) miR-34a-5p expression in previously untreated (UT) patients (n = 17) 
and patients having received prior therapy (PT) for CLL (n = 17) irrespective of genetic status, and 
of only TP53wt, 11q disomic status (UT n = 15, PT n = 9). Means and standard errors are 
indicated. Target gene expression was normalized to RNU6B and referenced to a HeLa sample. 
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were used for comparison to TP53del/mut samples (n = 10) to avoid impaired p53 pathway 
activity in previously treated TP53wt patients.  
 
3.3 Overview of RNA expression in primary CLL cells as captured by 
small RNA sequencing  
 
For small RNA sequencing, total RNA was extracted from 82 CLL primary samples (35 
patients, all treatments) and one pooled healthy B-cell control. RNA integrity numbers 
(RIN) as determined on an Agilent Bioanalyzer 2100 indicated that RNA was generally of 
sufficient quality (average RIN = 8.3, range 6.4-9.1, two samples below 7).  
Applying the aforementioned experimental approach and data analysis pipeline, 1.98 
billion reads were obtained from sequencing 84 small RNA libraries (= 82 + one technical 
replicate + healthy B-cells) (average 23.4 mio/sample) in total.  
Section 3.3.1 provides an overview of the transcript landscape captured by sequencing 
and mapping of all high-quality, adaptor-trimmed reads of at least 15 nt length to a set of 
coding and non-coding RNA databases as listed in 2.6.1. Basal miRNAs expression 
profiles in non-treated samples are presented in 3.3.2.  
3.3.1 RNA families detected by the approach 
Figure 16 illustrates the representation of different RNA family’s transcripts in the 
sequencing reads of at least 15 nt length. Ribosomal RNA, normally constituting 80-90% 
of cellular RNA228, was efficiently depleted, representing only 2% of all sequencing 
reads. Interestingly, only 13% of all reads mapped to mature miRNA sequences, 
whereas snoRNA were covered by most reads (22%), followed by mRNA represented by 
14%, down to lincRNA being covered by 1% of reads. 41% of reads did not map to any 
sequence of the curated set of reference databases, of which half (49%, i.e. 20% of total 
reads) were reads that did not map to the genome. In our selection of 17-25 nt long 
reads for miRNA expression analyses, 30% of reads mapped to mature miRNA (median; 
range 14 – 45%). Of the 1405 human mature miRNAs (miRBase v19), 1244 miRNAs 
were detected (≥ 1 read) in at least one CLL sample. We focused our analyses on 
miRNAs with an average of ≥ 5 reads across samples or a count of ≥ 10 in at least one 
sample. 
Although our screen was targeted at small RNA sequences to enrich for miRNA, the data 
on mRNA and other ncRNA expression was also analysed. 
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Figure 16. Expression of RNA subgroups detected by small RNA sequencing. Overview of 
read fractions mapping to different RNA families. Average values of n = 85 samples from 35 CLL 
patients and 1 pooled healthy B-cell sample. Relative abundance is expressed as percentage of 
total reads ≥15 nt. snoRNA = small nucleolar RNA; mRNA = messenger RNA); miRNA = mature 
microRNA, snRNA = small nuclear RNA; rRNA = ribosomal RNA; mt tRNA = mitochondrial 
transfer RNA; lincRNA = long intergenic ncRNA. 
 
3.3.2 miRNA expression profiles at baseline 
miRNA expression was quantified by mapping 17-25 nt long high quality reads to mature 
miRNA reference sequences of miRBase v19. Within this range of read lengths, isomiRs 
generated by 3’ or 5’ trimming of the miRNA reference sequence were subsumed in the 
total read count of the corresponding mature miRNA. For further analysis, read counts 
were corrected for batch effects between pilot and main screen, and normalized using 
DESeq2 in R. 
After 24 hours in culture without treatment (i.e. at baseline), expression profiles were 
dominated by miR-21-5p, a miRNA frequently overexpressed in malignancies229-231 
(Figure 17). Together with miR-26a-5p, let-7g-5p and miR-101-3p, it accounted for 51% 
of total miRNA reads. Nine of the 10 most strongly expressed miRNAs were previously 
reported among the 10 most abundant miRNAs in primary CLL cells (all except for miR-
148a-3p), although the top expressed miRNAs varied considerably between 
studies227,232,233.  
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Figure 17. Basal miRNA expression profiles detected by small RNA sequencing. Relative 
abundance is expressed as percentage of total mature miRNA sequence reads. Median values of 
n = 35 samples cultured for 24 hours without treatment are provided. The top 10 most abundant 
miRNA and their contribution to the overall miRNA read count are specified. The top 25 miRNAs 
shown on the chart. 
 
3.4 Identification of BCR signaling-dependent miRNA in CLL  
The identification of miRNAs involved in BCR signaling was approached from different 
angles: Firstly, as IGHV mutational status is connected to BCR signaling capacity, 
miRNAs differentially expressed in IGHV mutated compared to IGHV unmutated 
samples at baseline were identified. Secondly, dependency of miRNA expression on 
BCR signaling was directly tested by inhibition of the signaling pathway at the step of 
Bruton’s Tyrosine Kinase (BTK) using ibrutinib. Further, the correlation of miRNA 
expression profiles to in vitro ibrutinib sensitivity of primary CLL cells was assessed. 
 
3.4.1 Baseline miRNA expression and IGHV status  
To identify IGHV dependently expressed miRNA, the basal miRNA expression profiles of 
35 CLL patient samples of known IGHV mutation status were evaluated. Seven miRNAs 
were significantly overexpressed in samples of unmutated IGHV as compared to 
mutated IGHV, five were downregulated (Table 4), pointing towards potential 
involvement in BCR signaling. 
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Table 4. miRNAs differentially expressed with 
respect to IGHV status. Identified from miRNA 
expression profiles of n = 35 primary CLL samples. 
miRNA name 
U- 
IGHV 
M-
IGHV 
fold 
difference p-value 
Higher in U-IGHV 
miR-574-3p 241 115 2.0 0.009 
miR-184 30 9 3.3 0.009 
miR-330-3p 112 67 1.7 0.009 
miR-152 331 116 3.3 0.010 
miR-574-5p 163 76 2.0 0.014 
miR-9-5p 781 99 3.3 0.014 
miR-155-5p 44517 30945 1.4 0.041 
Lower in U-IGHV 
miR-514a-3p 3 13 0.2 0.003 
miR-29c-3p 1741 3736 0.5 0.009 
miR-141-3p 89 186 0.5 0.010 
miR-29c-5p 137 282 0.5 0.014 
miR-4432 2 6 0.3 0.042 
Normalized read counts are provided. U-IGHV = 
unmutated IGHV; M-IGHV = mutated IGHV. P-values 
were determined by Wald Test and corrected for 
multiple testing. 
Table 5. miRNA signature for 
the classification of samples 
according to IGHV status.  
Signature 
component coefficient 
miR-1246 0.10 
miR-138-5p -0.41 
miR-144-3p 1.03 
miR-151a-5p 1.11 
miR-181a-2-3p 0.14 
miR-181b-5p 1.29 
miR-193b-3p 0.25 
miR-29c-3p 1.34 
miR-29c-5p 0.90 
miR-365a-3p 0.67 
miR-365b-3p 0.00 
miR-4685-3p 2.67 
miR-511 -0.72 
miR-514a-3p 4.38 
miR-654-3p -1.60 
 
 
Using an L1 penalized logistic regression model for the development of signatures for 
sample classification, a miRNA expression signature composed of 15 components was 
found to discriminate between IGHV mutated and IGHV unmutated samples (Table 5). 
The performance of this IGHV status predictor was tested by leave-one-out 
crossvalidation, displaying an accuracy of 82%. The regression model provides a 
weighted classification rule, i.e. the coefficient indicated in Table 5 represents the weight 
of the respective miRNA for the classification. The higher the positive coefficient, the 
more a high expression level of the respective miRNA argues for the sample being IGHV 
mutated (e.g. miR-514a-3p). On the contrary, expression of a miRNA with a negative 
indicated coefficient will argue for the sample being IGHV unmutated (e.g. miR-654-3p). 
  
3.4.2 The impact of BTK inhibition on miRNA expression  
The BTK inhibitor Ibrutinib was used for abrogating the BCR signaling pathway in 
primary PBMNCs of 12 CLL patients. After a 24 hour treatment with 1 µM ibrutinib in 
vitro, the great majority of miRNAs did not change in expression as illustrated in Figure 
Results 
49 
 
18. However, miR-320c and miR-1246 were found upregulated, while miR-484, miR-17-
5p, miR-155-3p and miR-27a-5p were downregulated (Table 6).  
 
 
Figure 18. miRNA expression changes due to 1 µM ibrutinib treatment for 24 hours. 
Volcano plot displaying 397 expressed miRNAs, of which 6 are influenced by the treatment (p < 
0.05). miR-155-3p/5p, miR-27a-5p, and miR-132 have previously been described as BCR 
signaling dependent190,234. P-values were determined by Wald Test and corrected for multiple 
testing. 
 
Table 6. miRNAs differentially regulated upon ibrutinib treatment. Mean normalized read 
counts per group are provided. p-values were determined by Wald Test and Benjamini-Hochberg 
corrected. FC = fold change. 
 
miRNA name non-treated 
24h 
ibrutinib FC p-value 
upregulated 
    miR-320c 80 108 1.4 5.8E-04 
miR-1246 5587 7797 1.3 5.8E-04 
downregulated 
  miR-484 337 272 0.8 5.8E-04 
miR-17-5p 4191 3440 0.8 0.011 
miR-155-3p 21 10 0.5 0.018 
miR-27a-5p 245 159 0.7 0.034 
 
 
Whereas the expression changes caused by BCR signaling inhibition were subtle for 
most miRNAs, they were consistent across the samples (Figure 19). 
qPCR validation was attempted for miR-320c, miR-1246, miR-484 and miR-155-3p 
regulation, using miR-155-5p expression which was not influenced by the treatment as 
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control. The inhibitory effect of BCR signaling abrogation on miR-155-3p could be 
validated (fold change in qRT-PCR 0.6, p = 0.01), just as the steady expression of miR-
155-5p (fold change 1.3, p = 0.95). For the other candidates, the regulation as 
determined from the sequencing data was within the variability of the qRT-PCR assay. 
 
 
Figure 19. Expression of six ibrutinib-regulated miRNAs in 12 primary CLL samples in non-
treated (NT) condition and after 24h with 1 µM ibrutinib (PCI). P-values were determined by 
two-sided Student’s t-test. Dashed lines represent samples of unmutated IGHV status (n = 8), 
sold lines of mutated IGHV (n = 4) status. Every individual sample is encoded by one specific 
colour. 
 
No regulation of ncRNA expression beyond mature miRNAs (e.g. tRNA, lincRNA, etc.) 
was observed. 
 
3.4.3 Baseline miRNA expression and in vitro ibrutinib sensitivity  
Abrogation of BCR signaling with ibrutinib induces apoptosis in CLL tumor cells, and 
does so in an IGHV status dependent manner95,101. This could also be observed after 
treating the screen samples with 1 µM ibrutinib for 48 hours in vitro and measuring cell 
viability with CellTiter-Glo®. As illustrated in Figure 20, viability – indicated by the level of 
cellular ATP - was decreased to 83% over all samples (median; n = 34) at this timepoint. 
For IGHV mutated samples, viability dropped to 89% (median; n = 15), whereas viability 
was decreased to 77% in IGHV unmutated samples (median; n = 19) (p = 0.006). 
Viability data were kindly provided by Leopold Sellner.  
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Figure 20. Cell viability post in vitro ibrutinib treatment, stratified by IGHV status. Cell 
viability in all samples (n = 34), and separated into mutated IGHV (n = 15) and unmutated IGHV 
(n = 19), after 48 hour treatment with 1 µM Ibrutinib as determined by ATP-measurement with 
CellTiter-Glo®. Referenced to non-treated samples; mean and SEM are indicated. P-value was 
determined by two-sided Student’s t-test. 
 
We asked whether basal expression levels of specific miRNAs correlate to, and 
putatively influence, the treatment efficiency in vitro. To this end, basal miRNA 
expression levels were tested for differential expression in regard to cellular viability after 
treatment with ibrutinib. Because of outliers, the results were additionally tested for 
robustness using Cook’s distance measure. 10 miRNAs were found differentially 
expressed in regard to ibrutinib sensitivity, i.e. these miRNAs showed significant 
regulation upon 10% increase of cell viability post treatment (Figure 21 and Table 7). Of 
the 10, miR-23a, miR-23b and miR-24 are expressed from the same miRNA cluster. 
Three miRNAs, miR-574-5p, miR-155-5p and miR-4432 had been found to be IGHV 
status dependently expressed (refer to section 3.4.1). As miR-150-5p and miR-155-5p 
had been previously reported to regulate BCR signaling activity233,235, the potential 
involvement of the 10 miRNAs in regulating BCR signaling was investigated. The highly 
expressed miRNAs miR-23b-3p, miR-150-5p, miR-24-3p, miR-23a-3p and miR-155-5p 
were selected for identification of potential mRNA targets. To identify mRNAs which were 
inversely co-regulated with the expression of these miRNAs, and at the same time 
predicted targets of the respective miRNA, mRNA expression data generated from small 
RNA sequencing (see also section 3.5.2), the Pearson correlation coefficient and the 
miRanda, miRWalk and TargetScan target prediction algorithms were used. For miR-
150-5p, two potential mRNA targets were identified. The expression levels of the top hit, 
protein disulfide isomerase family A, member 6 (PDIA6) displayed a strong negative 
correlation to miR-150-5p expression (R = -0.75, p = 0.002) and was reported to be 
induced upon anti-IgM stimulation in CLL59. This opens up the possibility of BCR 
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signaling impairment by high miR-150-5p expression leading to ibrutinib resistance. The 
expression of Fc receptor-like protein 2 (FCRL2) correlated with and is targeted by miR-
23a-3p (R = -0.68, p = 0.04). It is an inhibitor of BCR signaling236 known to be 
downregulated in poor prognostic CLL237. It was also predicted to be targeted by miR-
155-5p (R = -0.68, p = 0.06). For miR-574-5p, 20 predicted targets displayed inverse co-
regulation (table S4), of which proto-oncogene PIM3, a serine/threonine kinase (R = -
0.64, p = 0.01) and transcription factor forkhead box O4 (FOXO4, R = -0.54, p = 0.04) 
were previously implicated in regulating BCR signaling and/or survival238-241. 
 
 
Figure 21. Hierarchical clustering of basal expression of miRNAs displaying robust 
differential expression in regard to CLL cell viability post in vitro ibrutinib treatment. 
miRNAs are presented in rows, CLL samples in columns. Median-centered, normalized 
expression levels are illustrated. Samples (n = 35) are sorted for cell viability post ibrutinib 
treatment (1 µM, 48 hours) as determined by CellTiter-Glo®. 
The baseline miRNA expression profiles could not be used to reliably predict in vitro 
ibrutinib sensitivity though (R2 = 0.2 for the correlation of observed viability after 
treatment to viability predicted using the L1 penalized linear regression model).  
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Table 7. miRNAs regulated with 10% increase of cell viability after 1 µM ibrutinib in vitro. n 
= 35 CLL samples. Normalized read counts and Benjamini-Hochberg corrected p-values are 
provided. 
miRNA name 
mean basal 
expression (reads) 
Fold 
change 
p-value 
miR-23b-3p 1146 0.8 0.007 
miR-4432 7 1.8 0.011 
miR-150-5p 138529 1.2 0.011 
miR-24-3p 7976 0.8 0.014 
miR-23a-3p 3094 0.8 0.015 
miR-548j 6 0.7 0.019 
miR-574-5p 205 0.8 0.019 
miR-155-5p 63468 0.9 0.029 
miR-1285-3p 39 0.9 0.032 
miR-330-5p 129 0.9 0.036 
 
3.4.4 Summary of BCR-dependent miRNAs in CLL 
The BCR signaling-dependent miRNA transcriptome in primary CLL was 
comprehensively assessed by small RNA sequencing. 12 miRNAs were found 
differentially expressed according to IGHV mutation status, which is a strong prognostic 
factor known to determine BCR signaling capacity. A miRNA signature made of 15 
components predicted IGHV status with good accuracy (82%). By ibrutinib-mediated 
BCR signaling inhibition at the stage of BTK, six regulated miRNAs were identified: miR-
320c and miR-1246 were induced, miR-484, miR-17-5p, miR-155-3p and miR-27a-5p 
were downregulated, implicating a role in BCR-signaling mediated support of cell 
survival. The basal expression of 10 miRNAs associated with in vitro sensitivity to 
ibrutinib treatment, and potentially influences BCR signaling capacity.  
  
Results 
54 
 
3.5 Identification of p53-dependent ncRNAs in primary CLL cells 
The impaired transcriptional activity of mutant p53 was used to identify ncRNAs 
dependent on p53 function in primary leukemia cells by comparison of DNA-damage 
triggered induction in TP53wt samples of previously untreated patients to TP53del/mut CLL. 
Analyses were performed separately for mature miRNAs, presented in section 3.5.1, and 
other ncRNAs, presented in section 3.5.4. For the latter, p53-dependency was assessed 
by two approaches: Firstly, by qRT-PCR based assessment of the expression of long 
intergenic non-coding RNA p21 (lincRNA-p21), a known p53 target in other cancer 
entities204. Secondly, by analysis of small RNA sequencing data for ncRNAs displaying 
TP53 status dependent induction after irradiation. 
 
3.5.1 TP53 status dependent miRNA induction 
In the absence of DNA damage induction, no differentially expressed miRNAs were 
found in TP53wt compared to TP53del/mut, but the lower expression of miR-34a-5p in 
TP53del/mut (97 vs. 29 reads; p = 0.16) was confirmed. In an unsupervised hierarchical 
clustering, samples clustered by patient (data not shown), reflecting inter-patient 
heterogeneity. 
Across all CLL samples, there was a strong correlation of miRNA expression in 
untreated versus irradiated CLL cells (median R2 = 0.98), suggesting that the 
transcriptional profile is not altered for the great majority of miRNAs. An overview of 
irradiation-induced miRNA expression changes related to genetic and clinical parameters 
of our test cohort by unsupervised hierarchical clustering (Figure 21) demonstrated that 
the miRNA signature was not sufficient to identify the patient’s genetic or treatment 
status, although most samples carrying TP53del/mut or del11q clustered together. 
Subsequently, DNA damage triggered miRNA induction in TP53wt was compared to 
TP53del/mut samples. A more dynamic expression change was observed in the p53 wild-
type CLLs, where 36 miRNAs were regulated in response to DNA damage compared to 
12 in the group with p53 loss/mutation (Table 8). While a set of miRNAs including miR-
150-3p, miR-155-5p and miR-92a-3p was uniformly regulated in the genetic subgroups 
suggesting a p53-independent role upon DNA-damage, 23 miRNAs showed substantially 
different regulation in TP53wt compared to TP53del/mut samples, albeit some at very low 
expression levels (Table 8, bold print). miR-34a-5p was the most strongly induced target 
in TP53wt but not in TP53del/mut samples (4.3 fold, p < 0.001 vs. 2.9 fold, p < 0.001). 
Further, the expression of a set of miRNAs including miR-182-5p, miR-7-5p and miR-
320d/c was found up-regulated after IR in TP53wt, but not TP53del/mut samples, indicating 
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p53-dependent transcriptional regulation (see also S1). p53-dependent miR-34a-5p 
expression had been validated by qRT-PCR (Figure 14). 
 
 
Figure 22. Unsupervised hierarchical clustering of IR-induced expression changes of the 
300 most variably expressed miRNAs over 34 CLL patient samples. Genetic and clinical data 
are provided (grey = no, black = yes). Each row represents a miRNA, each column represents a 
sample. The colour scale illustrates the median-centered, relative expression change of a miRNA 
(red = higher, blue = lower than median). 
 
Additionally, miR-7-5p and -320d regulation upon IR was successfully validated by qRT-
PCR (median miR-7-5p TP53wt (n = 10): 2.4 fold, p = .001; TP53del/mut (n = 6): 1.0 fold, p 
= .31; median miR-320d TP53wt (n = 11): 1.7 fold, p = .01; TP53del/mut (n = 7): 1.0 fold, p = 
.37). Our data furthermore support a p53-dependent regulation of miR-320d family 
members miR-320c and miR-320b sharing the same seed sequence (Table 8). 
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Table 8A. miRNAs regulated upon DNA damage in TP53wt (n = 15) CLL samples. miRNAs 
regulated upon IR in TP53wt but not in TP53del/mut cases, or vice versa, are highlighted*. Mean 
normalized read counts 24h post NT (no treatment) or IR (irradiation) are provided. P-values are 
Benjamini-Hochberg corrected for multiple testing.  
*miRNA selection criteria: A fold change (FC) difference of ≥0.3 between TP53wt and TP53del/mut, 
and a p-value of < 0.05 in at least one of both groups, and a difference in p-values of ≥ 1 log10. 
miRNA  TP53wt TP53del/mut TP53wt TP53del/mut TP53wt TP53del/mut 
 NT IR NT IR FC FC p-value p-value 
miR-34a-5p 97 370 29 115 4.3 2.9 4.3E-39 2.3E-04 
miR-150-3p 302 180 292 172 0.6 0.6 9.3E-18 1.3E-07 
miR-182-5p 98 158 149 170 1.6 1.2 6.7E-10 0.221 
miR-7-5p 1218 1767 1508 1672 1.5 1.1 4.4E-08 0.671 
miR-155-5p 33921 47139 43778 54809 1.4 1.3 6.2E-07 3.6E-04 
miR-320d 39 69 59 57 1.7 1.0 7.6E-07 0.984 
miR-320c 69 116 101 98 1.6 1.0 7.6E-07 0.990 
miR-21-3p 223 323 375 458 1.5 1.3 9.0E-07 0.026 
miR-574-5p 83 116 147 154 1.4 1.1 2.6E-05 0.918 
miR-9-5p 115 167 1203 1299 1.5 1.1 8.4E-05 0.923 
miR-34a-3p 1 4 0 1 8.4 8.7 8.6E-05 1.000 
miR-92a-3p 15619 18608 15648 18329 1.2 1.2 1.2E-04 0.221 
miR-23a-3p 1958 2496 2515 2546 1.3 1.0 1.2E-04 0.984 
miR-320b 168 237 267 256 1.4 1.0 2.3E-04 0.984 
miR-186-5p 6295 5499 5903 5903 0.9 1.0 9.9E-06 0.984 
miR-181d 5 11 11 16 2.1 1.6 3.6E-04 0.501 
miR-29b-1-5p 18 9 15 17 0.5 1.1 5.8E-04 0.936 
miR-24-3p 4276 5020 5773 6360 1.2 1.1 0.003 0.034 
miR-1260b 10 4 11 10 0.5 1.0 0.003 0.984 
miR-26a-2-3p 129 75 92 78 0.6 0.9 0.004 0.921 
miR-339-5p 787 606 591 573 0.8 1.0 0.006 0.936 
miR-181c-3p 5 11 10 15 2.1 1.6 0.006 0.605 
miR-28-5p 1206 1027 1200 1204 0.8 1.0 0.009 0.990 
miR-183-5p 29 39 37 43 1.4 1.4 0.009 0.501 
miR-335-5p 487 415 486 475 0.8 1.0 0.012 0.936 
miR-582-5p 3 7 2 6 2.2 1.5 0.014 0.928 
miR-27a-5p 240 317 390 454 1.3 1.2 0.014 0.221 
miR-15a-5p 1266 1063 705 675 0.8 1.1 0.017 0.928 
miR-3653 182 255 207 178 1.3 0.9 0.020 0.928 
miR-142-3p 25133 22119 21751 23157 0.9 1.1 0.020 0.928 
miR-6724-5p 5 3 4 3 0.4 0.8 0.021 1.000 
let-7i-5p 49359 58378 56522 60268 1.2 1.1 0.023 1.000 
miR-27a-3p 16001 18532 19466 23169 1.2 1.2 0.035 0.006 
miR-3609 61 81 82 78 1.2 0.9 0.035 0.936 
miR-17-5p 3710 4538 3285 4696 1.2 1.4 0.035 1.3E-04 
miR-339-3p 393 347 351 335 0.9 1.0 0.043 0.984 
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Table 8B. miRNAs regulated upon DNA damage in TP53del/mut CLL (n = 10) not listed in 
A. . 
miRNA  TP53wt TP53del/mut TP53wt TP53del/mut TP53wt TP53del/mut 
 NT IR NT IR FC FC p-value p-value 
miR-18a-5p 71 73 61 95 1.0 1.6 0.902 0.002 
miR-20a-5p 16613 18664 15483 19367 1.1 1.3 0.432 0.004 
miR-155-3p 14 17 19 36 1.2 1.8 0.578 0.011 
miR-1246 8040 10090 12275 9635 1.2 0.8 0.213 0.025 
miR-22-3p 2733 2876 3037 3451 1.0 1.1 0.839 0.026 
 
On the contrary, three miRNAs were regulated in the TP53 del/mut but not TP53wt 
samples (Table 8B), suggesting a p53-independent role in resistance to DNA damage-
induced apoptosis. 
3.5.2 Deriving insights into the regulation of long RNA transcripts from a 
small RNA sequencing screen  
The small RNA sequencing reads had been mapped to a set of ncRNA families and 
mRNA (section 3.3.1). In order to investigate whether these expression data derived 
from fragments of longer RNAs would be informative, i.e. whether the fragment quantity 
would reflect the parent RNA expression and could be used for analyses, irradiation-
induced mRNA expression changes in previously untreated TP53wt were compared to 
TP53del/mut samples.  
In the wild-type setting, 792 mRNA transcripts were found significantly regulated as 
opposed to 15 in p53 aberrant samples. Table 9 compares the 10 most strongly 
regulated mRNAs in the TP53wt samples and well-established p53 targets Bax242,243 and 
GADD45A153,244 to their expression and induction in TP53del/mut CLLs. Key p53 targets 
MDM2 and CDKN1A (p21) ranked among the top five induced mRNAs in TP53wt, but 
showed no significant induction in TP53del/mut. The same regulation was also observed for 
Bax and GADD45A. In line with this, all of the top 10 regulated mRNAs displaying 
induction exclusively in the wild-type setting were known p53 targets (bold print; 
RPS19206,208,243, MDM2245, PLXNB2246, TRIM22243, CDKN1A247,248, PCNA153, 
TNFRSF10B153, ASCC3208, BBC3 (PUMA)206,249). TP53 status dependent induction was 
not a bystander effect of higher RNA fragmentation in irradiated TP53wt than TP53del/mut 
samples caused by higher apoptosis rates in TP53wt (Figure 12), since the mean RIN for 
both TP53 groups after IR was 8.2. The expression values of p21/CDKN1A post 
irradiation as determined by qRT-PCR and smRNA sequencing correlated well (R2 = 
0.65) over all samples. 
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These data strongly suggested that small RNA sequencing was representative even for 
longer transcripts. 
 
Table 9. Top mRNAs induced in previously untreated TP53wt compared to TP53del/mut 
samples 24 h post irradiation. Known p53 targets are marked by bold print. Mean normalized 
read counts and Benjamini-Hochberg corrected p-values are provided. NT = non-treated, IR = 
irradiated, FC = fold change.  
Rank mRNA name TP53wt TP53del/mut TP53wt TP53del/mut TP53wt TP53del/mut 
  NT IR NT IR FC FC p-value p-value 
1 RPS19 140 387 121 185 2.7 0.7 3.6E-40 0.015 
2 MDM2 92 390 81 179 4.1 1.9 4.7E-40 0.178 
3 PLXNB2 28 103 24 42 3.7 1.6 4.3E-22 0.154 
4 TRIM22 61 144 64 78 2.3 1.1 7.2E-21 1.000 
5 CDKN1A 10 44 11 21 4.5 1.9 1.1E-19 0.207 
6 PCNA 17 50 19 27 2.8 1.4 2.1E-15 1.000 
7 TNFRSF10B 34 80 33 41 2.3 1.2 8.9E-14 1.000 
8 EEF1A1 1139 1829 1249 1741 1.6 1.4 4.9E-13 5.2E-4 
9 ASCC3 72 132 70 84 1.8 1.2 1.5E-12 1.000 
10 BBC3 9 29 7 14 3.2 1.7 1.8E-12 1.000 
17 BAX 29 55 27 33 1.9 1.3 5.6E-9 1.000 
78 GADD45A 11 21 9 14 2.0 1.6 6.6E-5 1.000 
 
3.5.3 Potential targets of p53-dependently regulated miRNAs in CLL 
Target prediction for miR-34a-5p, miR-182-5p, miR-7-5p and miR-320c/d was performed 
in Ingenuity® (based on the TargetScan algorithm). Only mRNAs significantly 
downregulated after DNA damage in TP53wt samples were analysed. Table 10 
summarizes all predicted mRNA targets for which a role in cell proliferation and/or 
survival has been previously reported, and which were predicted to be targeted by the 
respective miRNA by at least one additional database tool (TarBase250, miRanda118, 
miRwalk223, PicTar251). Induction of miR-182-5p, for example, correlates with a reduction 
of nuclear receptor subfamily 1, group D, member 2 (NR1D2) mRNA, which was 
suggested to negatively regulate p21 expression252. It further correlates with a 
downregulation of O-linked β-N-acetylglucosamine transferase (OGT) mRNA levels. 
OGT has been shown to affect the phosphorylation of ATM, fostering p53 activation253. 
Moreover, miR-182-5p induction correlates with reduction of cAMP-dependent protein 
kinase type I-alpha regulatory subunit 1 alpha (PRKAR1A) mRNA. PRKAR1A is 
overexpressed in a variety of tumors254 and a loss of function was shown to cause 
apoptosis via BCL2255. 
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Table 10. mRNAs predicted to be targeted by p53-dependent miRNAs upon DNA damage. 
Gene names of high confidence targets (TargetScan) are listed. FC, fold change after irradiation 
(5 Gy) in TP53wt CLL. 
miRNA name 
 
FC mRNA target (gene) FC 
Involved in 
proliferation/survival, 
reference 
miRNA-34a-5p 4.3 E2F5 0.6 256,257 
  MDM4 0.8 258,259 
miR-182-5p 1.6 NR1D2 0.7 252 
  OGT 0.8 253 
  PRKAR1A 0.8 254,255 
miR-7-5p 1.5 OGT 0.8 253 
  PRKCB 0.8 260,261 
miR-320c/d 1.7 NR1D2 0.7 252 
  PCDH9 0.7 69 
  PRKAR1A 0.8 254,255 
  YWHAZ 0.8 262 
 
 
3.5.4 p53 dependent long non-coding RNA induction 
3.5.4.1 lincRNA-p21 in CLL 
qRT-PCR quantification of lincRNA-p21 expression upon irradiation-triggered p53 
activation revealed a significantly stronger induction in TP53wt (n = 19, p = 0.005) than 
TP53del/mut CLL (n = 10, p = 0.08) (median 16.5 vs. 3.0 fold, p = 0.001), while samples 
with del11q displayed a medium induction (n = 5, p = 0.04, median 16.5 vs. 7.7 fold, p = 
0.11) (Figure 23 A, B). 
These results were validated in an independent cohort of 39 CLL patients (Figure 23 C, 
D). Brisk lincRNA-p21 induction was again observed after DNA damage in TP53wt CLL (p 
< 0.001, median induction 16.3 fold) but not in p53 deficient CLL (p = 0.27, induction 1.3 
fold; Figure 23 D).  
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Figure 23. DNA damage triggered lincRNA-p21 induction in CLL. . (A, B) lincRNA-p21 
expression in samples of n = 34 CLL patients left untreated for 24h or 24h post irradiation (IR, 5 
Gy), grouped into TP53wt and 11q23 disomic, TP53wt with del11q23, and TP53del/mut as in Figure 
14. (C, D) LincRNA-p21 induction in a validation cohort of CLL patients (n = 36). Median ± SEM 
are indicated.  
 
We observed a strong correlation of lincRNA-p21 with induction of p21 and with 
reduction of cell viability due to apoptosis, a major endpoint of p53 activation (Figure 24 
A, B).  
Cp values across all samples post irradiation ranged between 29.0 and 35.6, indicating 
low expression. 
 
 
A
C
IR - + - + - +
TP53wt del11q TP53del/mut
p = 0.005
IR - + - + - +
TP53wt del11q TP53del/mut
p = 0.04 p = 0.08
p = 0.04
p = 0.56
p < 0.001 p = 0.07 p = 0.27
p < 0.001
p = 0.38
t t t t
0.1
1
10
100
1000
10000
re
la
tiv
e
lin
cR
N
A-
p2
1 
ex
pr
es
si
on
0.01
0.1
1
10
100
1000
re
la
tiv
e
lin
cR
N
A-
p2
1 
ex
pr
es
si
on
p = 0.07
p = 0.06
wt
TP
53
de
l11
q 
de
l/m
ut
TP
53
-5
0
5
10
 
lo
g 2
 li
nc
R
N
A
-p
21
 fo
ld
 in
du
ct
io
n 
(IR
)
p = 0.001
p = 0.11
D
B
p < 0.001
p = 0.07
wt
TP
53
de
l11
q 
de
l/m
ut
TP
53
-5
0
5
10
 
lo
g 2
 li
nc
R
N
A
-p
21
 fo
ld
 in
du
ct
io
n 
(IR
)
Results 
61 
 
 
Figure 24. Correlation of DNA-damage triggered lincRNA-p21 induction with p21 induction 
and cell viability. (A) LincRNA-p21 vs. p21 expression after IR in the test cohort. Median ± SD 
are indicated. (B) Correlation of lincRNA-p21 induction with cellular viability as determined by 
double negativity in FACS Annexin V / PI staining of the test cohort samples. 
 
To support p53-dependence of expression in the absence of DNA damage induction, 
primary CLL cells were exposed for 24 hours to 10 µM of the MDM2 inhibitor nutlin-3 
selectively stabilizing p53. Likewise, nutlin-3 led to induction of lincRNA-p21 expression 
exclusively in TP53wt (n = 7, median 5.3 fold), but not TP53del/mut samples (n = 3, median 
1.1 fold) (Figure 25).  
 
Figure 25. LincRNA-p21 expression 24 h post induction with 10 µM nutlin-3 or vehicle 
control in primary CLL samples. Expression was determined by qRT-PCR in n = 8 p53wt 
samples and n = 3 p53del/mut samples. Means ± SEM are indicated. 
 
 
3.5.2.3 NEAT1 in CLL 
In order to identify p53-dependent ncRNAs beyond mature miRNAs, all reads ≥ 15 nt 
which did not correspond to mature miRNA sequences were mapped to a set of ncRNA 
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reference sequences curated from Ensembl 71, GtRNAdb217, Rfam 11.0, and the piRNA 
cluster database218. From this, a list of DNA damage induced ncRNA in primary CLL was 
generated (Table 11). The precursor of miR-34a was the top IR-induced ncRNA. Directly 
following pre-miR-34a, two transcripts of NEAT1 (nuclear enriched abundant transcript 
1), a lincRNA constituting a major component of the nuclear paraspeckles of mammalian 
cells263, showed distinct p53-dependent induction after IR.  
In total, three overlapping NEAT1 transcript sequences were captured - NEAT1-002 (1.8 
kb), NEAT1-202 (1.5 kb) and NEAT1-001 (22.7 kb; Figure 26A) - originating from the 
22.8 kb long NEAT1 gene located on chromosome 11q13.1 (11:65,190,245-65,213,011 
Ensembl GRCh37). In contrast to NEAT1-002 and NEAT-202, NEAT1-001 was not 
found regulated by DNA damage (mean fold change TP53wt 1.1, p = 0.32; TP53del/mut 1.0, 
p = 0.99). DNA damage-triggered NEAT1-202 and NEAT1-002 induction in previously 
untreated TP53wt was significantly stronger than in TP53del/mut samples (TP53wt mean 
NEAT1-202/NEAT1-002 induction 2.0/1.8 fold, p < 0.001; TP53del/mut mean NEAT1-
202/NEAT1-002 induction 1.3/1.3 fold, p = 0.22/0.03; Table 11 and Figure 26 B, C). 
NEAT1-202 and NEAT1-002 normalized read counts over all samples strongly correlated 
(R2 = 0.91), which was expected due to high sequence similarity of the transcripts. 
 
Table 11. Top 10 ncRNAs induced in previously untreated TP53wt compared to TP53del/mut 
samples 24 h post irradiation. Mature miRNAs were excluded. Mean normalized read counts 
and Benjamini-Hochberg corrected p-values are provided. FC = fold change.  
RNA name TP53wt TP53del/mut TP53wt TP53del/mut TP53wt TP53del/mut 
 NT IR NT IR FC FC p-value p-value 
pre-miR-34a 200 853 70 314 4.6 3.5 1.07E-34 2.50E-07 
NEAT1-202 40 84 41 52 2.0 1.3 8.43E-24 0.222 
NEAT1-002 61 115 58 77 1.8 1.3 5.04E-17 0.025 
trna8-LysCTT 358 642 354 401 1.8 1.1 5.12E-11 0.811 
tRNA 385 669 397 460 1.7 1.1 5.12E-11 0.444 
trna30-LysCTT 703 1036 771 880 1.5 1.2 1.58E-10 0.201 
trna119-LysCTT 4063 5796 4212 6176 1.4 1.4 4.00E-09 2.29E-16 
trna10-LysCTT 5366 8067 5003 7175 1.5 1.4 4.97E-07 4.84E-13 
trna13-LysCTT 8107 12173 7243 9670 1.5 1.4 1.24E-06 2.01E-07 
trna1-SeC(e)TCA 343 584 215 315 1.7 1.4 1.68E-06 0.085 
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Figure 26. NEAT1 induction upon DNA damage in primary CLL cells. (A) NEAT1 transcripts 
as originating from the 22.77 kb long NEAT1 gene on chromosome 11q as in Ensembl GRCh37. 
Localization of the qRT-PCR amplicon is indicated. (B, C) NEAT1-202 and NEAT1-002 
expression as determined by sequencing (see Table 11) in non-treated (NT) and irradiated (IR) 
samples of TP53wt and TP53del/mut status, and (D) as determined by qRT-PCR in identical 
samples. In B and C, P-values were calculated using the Wald test and corrected for multiple 
testing. In D, two-sided Student’s t-test was applied.  
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NEAT1 expression levels were validated by qRT-PCR detecting an amplicon in the 5’ 
end of the 2nd exon of NEAT1-002, i.e. detecting all three NEAT1 transcripts (Figure 26 
A, D and Figure 27). As in the sequencing data, NEAT1 expression after IR was 
significantly higher in TP53wt than TP53del/mut samples (p < 0.001, Figure 27 A). Cp values 
of irradiated samples ranged between 19.5 and 23.7, indicating high NEAT1 expression. 
Thus, the moderate average induction of 2.8-fold (qRT-PCR) in TP53wt samples reflected 
a strong addition in NEAT1 transcript amount upon DNA damage.  
Samples harboring del11q displayed a tendency towards diminished NEAT1 induction as 
illustrated in Figure 27 A, B (TP53wt median 2.9 fold; del11q 1.9 fold; TP53mut/del 1.3 fold). 
 
 
Figure 27. NEAT1 expression 24 hours after irradiation (IR) or no treatment (NT) of primary 
CLL cells. (A) NEAT1 expression at NT state or post IR, stratified by TP53 and 11q status. (B) 
DNA damage-triggered NEAT1 induction stratified by TP53 and 11q status. P-values were 
calculated by two-sided Student’s t-test. (C) Correlation of NEAT1 and p21 expression in 
irradiated samples. All data were generated by qRT-PCR.  
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The level of NEAT1 and p21 expression after DNA damage strongly correlated (Figure 
27 C), indicating a common regulatory mechanism. The correlation of NEAT1 expression 
to the fraction of apoptotic cells was low (R2 = 0.19, p = 0.28; data not shown).  
Targeted activation of p53 by nutlin-3 treatment of primary CLL cells induced cellular 
apoptosis in TP53wt samples (p < 0.001) but not in the presence of TP53 aberrations (p = 
0.35). At the same time, NEAT1 expression was induced in TP53wt (p < 0.001) but not 
TP53del/mut samples (p = 0.30) (Figure 28), confirming p53-dependent regulation. 
 
 
Figure 28. NEAT1 expression 24 h post induction with 10 µM nutlin-3 or vehicle control in 
primary CLL samples. Expression was determined by qRT-PCR in n = 10 TP53wt samples and n 
= 5 TP53del/mut samples. Means ± SEM are indicated. 
 
 
3.5.5 Comparison of p53 pathway activity in treated and untreated TP53 
wild-type CLL 
TP53 aberrations in CLL associate with relapse after therapy, but not all relapsed CLL 
patients carry mutant p53264,47. To determine factors causing poor therapy response in 
the wild-type setting, p53 pathway activity was assessed in nine previously treated, high-
risk TP53wt CLLs and compared to samples of TP53wt patients who had not received 
prior therapy for CLL.  
In treated TP53wt CLLs, only three miRNAs were regulated upon IR-induced p53 
activation: miR-34a-5p (fold change (FC) 4.1, p < 0.001), miR-150-3p (FC 0.7, p = 0.002) 
and miR-21-3p (FC 1.3, p = 0.03). This is in contrast to the dynamic response observed 
in samples of TP53wt, untreated patients, where 36 miRNAs were regulated (Table 8). 
The expression of p53 targets miR-182-5p, miR-7-5p and miR-320d/c was unchanged 
upon DNA damage in TP53wt high-risk patient samples (miR-182-5p FC 1.3, p = 0.68; 
miR-7-5p FC 1.1, p = 0.84; miR-320d FC 0.9, p = 0.97, miR-320c FC 1.0, p = 0.98). 
Similarly, treated TP53wt CLLs displayed reduced lincRNA-p21 and NEAT1 induction 
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(Figure 29, PT median 4.2 fold and 2.0 fold, respectively) compared to untreated (UT) 
TP53wt CLLs (median 20.7 fold and 2.9 fold, respectively; p = 0.03 for lincRNA-p21 and p 
= 0.01 for NEAT1). This was independent from the treated TP53wt patients’ ATM status, 
as lincRNA-p21 induction was diminished to 7.9 fold (median) also in disomic 11q and 
wild-type ATM samples (p = 0.17, Figure 29 A). This was comparable for NEAT1, where 
induction in the high-risk group with ATM aberrations was 2.0 fold (n = 6), just as for 
ATM normal samples (median 2.0 fold, n = 3; p = 0.60), both being far lower than the 
induction in 11q disomic ATMwt, TP53wt samples of untreated patients. This is in keeping 
with the observations for p21 (refer to section 3.2). Together, this points towards 
impaired p53 pathway activity in treated TP53wt high-risk CLLs, which is independent 
from aberrations of ATM. 
 
 
Figure 29. Induction of lincRNA-p21 and NEAT1 in CLL stratified by patient treatment, TP53 
and ATM status. (A) lincRNA-p21 fold induction and (B) NEAT1 fold induction in CLL-PBMNCs 
24 hours post 5 Gy irradiation stratified by patient treatment status, indicating samples derived 
from patients that were previously untreated (UT), or had received prior therapy (PT) for CLL. The 
four groups on the right display TP53wt samples only, stratified by treatment (UT = 15, PT = 9) 
and ATM status (aberrant n = 6; normal n = 3). The PT TP53wt patients had all relapsed within 26 
months after therapy. Means and standard errors are indicated. P-values were calculated by 
Student’s t-test. 
 
To explore possible mechanisms of p53 deactivation in treated TP53wt patients, baseline 
miRNA profiles were compared between untreated TP53wt and treated, high-risk TP53wt 
CLLs. After additional testing for robustness using Cook’s distance measure, miR-1285-
3p and let-7b-5p were found higher expressed in samples from treated patients (fold 
difference 1.9 and 2.2, p < 0.05). Interestingly, miR-1285-3p was reported to target p53 
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mRNA265. However, no direct correlation between baseline miR-1285-3p expression and 
p53 activity indicated by IR-triggered p21 induction was observed (n = 35, R2 = 0.05). 
Still, TP53wt high-risk patient samples expressing high miR-1285-3p (> median) 
displayed a tendency towards lower p21 induction (average 5.8 fold) than low expressing 
samples (average 10.1 fold, p = 0.22). Let-7b is predicted to target the mRNA of p53 and 
TP53 regulating kinase (miRanda, miRWalk and TargetScan). Again, no direct 
correlation of basal expression to p21 induction post irradiation was found (R2 = 0.04). 
High (> median) let-7b-5p expressing samples showed only slightly lower p21 induction 
than low let-7b-5p (< median) expressors (6.0 vs. 9.1, p = 0.40). In addition, basal non-
miRNA ncRNA expression was compared between previously untreated TP53wt patients 
and treated TP53wt patients. As displayed in table S5, nine transcripts were differentially 
expressed, whereas for none of them, a function in the p53 pathway has been previously 
reported. In conclusion, no overexpression of a known ncRNA repressor of the p53 
pathway was found in treated, high-risk TP53wt patients. 
 
3.6 p53 dependency of lincRNA-p21 and NEAT1 expression in the 
Burkitt’s Lymphoma (BL) cell line model  
To assess lincRNA-p21 and NEAT1 regulation in other lymphoma subtypes, a large set 
of Burkitt’s Lymphoma derived B-cell lines of disparate TP53 status was chosen. In this 
model, p53-dependency of NEAT1 and lincRNA-p21 was investigated in more detail. 
3.6.1 lincRNA-p21 and NEAT1 induction in BL cell lines  
Induction dynamics of lincRNA-p21 and NEAT1 expression in response to IR-mediated 
DNA damage were studied in a set of 11 genetically unmodified Burkitt’s lymphoma cell 
lines, of which six were TP53wt, seven TP53mut (table S2) as illustrated in Figure 30. 
In analogy to the observations in CLL, lincRNA-p21 was induced 24 hours post 5 Gy IR 
in the TP53wt cell lines only, while none of the TP53mut cell lines showed an increase in 
expression (Figure 30 A), supporting a direct regulation by p53. The induction observed 
in the wild-type setting was heterogeneous, ranging from 22.0 fold (BL-7) to 1.9 fold 
(Seraphine).  
NEAT1 induction was more subtle and did not separate the cell lines by TP53 mutation 
status as clearly (Figure 30 B). Still, at 24 hours after IR, TP53wt displayed a clear 
tendency towards higher NEAT1 induction (mean 2.5 fold) than TP53mut cell lines (mean 
1.1 fold) (p = 0.07).  
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Figure 30. Time course of lincRNA-p21 and NEAT1 induction in TP53wt and TP53mut 
Burkitt’s Lymphoma cell lines. (A) lincRNA-p21 and (B) NEAT1 induction in TP53wt (blue) and 
TP53mut (black) Burkitt’s Lymphoma cell lines after 5 Gy irradiation (IR) was monitored for up to 24 
hours (h). Expression levels are relative to the non-irradiated sample (normalized to lamin B1) 
determined by qRT-PCR. 
 
3.6.2 NEAT1 and lincRNA-p21 expression in BL cell line models of 
controlled p53 expression 
To finally prove p53-dependency of NEAT1 and lincRNA-p21 expression, modified 
Salina and Seraphine cells (p53wt) with p53 expression controlled by shRNA mediated 
knockdown (p53kd, Salina) or CRISPR/Cas9 mediated p53 knockout (p53ko, Seraphine) 
as well as p53 mutant Namalwa (p53mut) were used. The cell lines were exposed to 
nutlin-3 for 6 or 24 hours or treated with vehicle control. A concentration- and time-
dependent, nutlin-3 triggered induction of p53 protein levels was observed in the wild-
type setting (Figure 31).  
 
 
Figure 31. Effect of nutlin-3 treatment on p53 expression in BL cell lines of defined p53 
status. (A) p53 and expression after 6 h treatment with 0-10 µM nutlin-3 determined by Western 
Blot. (B) p53 expression after 24 h treatment with 0-10 µM nutlin-3. GAPDH served as loading 
control.  
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Figure 32. Effect of nutlin-3 treatment on apoptosis in BL cell lines of defined p53 status. 
Wild-type p53 (p53wt), p53 mutation (p53mut), shRNA-mediated p53 knockdown (p53kd) or 
CRISPR/Cas9 mediated knockout (p53ko) cell lines were subjected to treatment with nutlin-3 or 
solvent control (DMSO). The fraction of apoptotic cells was measured by APC-coupled Annexin V 
staining in FACS. (A) Exemplary scatter plots displaying the fraction of apoptotic cells (blue) post 
24 h DMSO solvent control or 10 µM nutlin-3 in Salina p53wt and (B) Salina p53kd cells. (C) 
Summary of nutlin-3 concentration dependent fraction of apoptotic, Annexin V positive cells in 
FACS after 24 h for all cell lines.  
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nutlin-triggered p53 stabilization. Residual p53 expression in the p53ko cells was 
attributable to the pooled nature of the approach; the knockout was present in 80% of 
cells as confirmed by 454 sequencing. p53 mutant Namalwa displayed strong 
overexpression of (non-functional) p53, as expected. Induction of apoptosis in these p53 
aberrant cell lines was negligible.  
 
 
 
Figure 33. Expression of p21, lincRNA-p21 and NEAT1 upon nutlin-3 treatment of primary 
CLL and BL cell lines. (A) Expression and fold induction of p21, (B) lincRNA-p21 and (C) 
NEAT1 after 24 hours of treatment with 0-10 µM nutlin-3 as assessed by qRT-PCR. Values were 
normalized to Lamin B1 and referenced to a HeLa sample. Induction was calculated as fold 
change compared to solvent control (DMSO). The legend in A is applicable to all panels of this 
figure. 
 
Induction of p21, lincRNA-p21 and, most importantly, NEAT1 were monitored by qRT-
PCR. Their expression levels tightly correlated to those of p53 (Figure 31). Apoptosis 
induction strongly correlated with induction of NEAT1 (R2 = 0.75), and moderately with 
 
DM
SO
2.5
 µM
10
 µM
10
100
1000
10000
100000
 
 
 
 
 
no
rm
al
iz
ed
 to
 H
eL
a,
 %
 
DM
SO
2.5
 µM
10
 µM
10
100
1000
10000
 
 
 
 
lin
cR
N
A-
p2
1 
ex
pr
es
si
on
no
rm
al
iz
ed
 to
 H
eL
a,
 %
re
la
tiv
e 
p2
1 
ex
pr
es
si
on
re
la
tiv
e 
lin
cR
N
A
-p
21
 e
xp
re
ss
io
n
B
A
  
  
 
  
 
 
 
Salina p53wt
Salina p53kd 
Seraphine p53wt
Seraphine p53ko
Namalwa p53mut
 
2.5
 µM
10
 µM
0
20
40
60
80
100
 
 
 
 
p2
1 
fo
ld
 in
du
ct
io
n
(n
ut
lin
-3
)
 
2.5
 µM
10
 µM
0
20
40
60
80
 
 
 
 
lin
cR
N
A-
p2
1 
fo
ld
 in
du
ct
io
n
(n
ut
lin
-3
)
  
DM
SO
2,5
µM
10
µM
0.1
1
10
100
 
 
 
 
N
EA
T1
 e
xp
re
ss
io
n
no
rm
al
iz
ed
 to
 H
eL
a
re
la
tiv
e 
N
EA
T1
 e
xp
re
ss
io
n
C
 
2.5
 µM
10
 µM
0
5
10
15
20
 
 
 
 
N
EA
T1
 fo
ld
 in
du
ct
io
n
(n
ut
lin
-3
)
Results 
71 
 
induction of lincRNA-p21 (R2 = 0.32) and p21 (R2 = 0.35). For all three RNAs, nutlin-3 
triggered induction was pronounced in the Seraphine and Salina p53wt cell lines and 
reduced in the p53 knockdown / p53ko and p53mut cells. These data strongly suggest a 
role of p53 in regulating lincRNA-p21 and NEAT1 transcription not only in primary CLL 
cells, but also in cellular models of Burkitt’s Lymphoma. 
 
3.6.3 Assessment of p53 binding to the NEAT1 promoter 
To determine whether p53 binds to the NEAT1 promoter and to rule out indirect 
regulation of NEAT1 expression by a p53 target, we made use of the Burkitt’s lymphoma 
cell line models of controlled p53 expression. 24 hours upon treatment with 10 µM nutlin-
3, Séraphine p53wt and isogenic p53ko cells were harvested, DNA was sheared to 300-
400 bp (Figure 34 A) and subjected to ChIP with p53 antibodies. Subsequently, the 
NEAT1 promoter sequence was amplified by PCR, using self-designed primers targeting 
a published p53 binding site upstream of NEAT1206. As displayed in Figure 34 B, p53 
was found to bind to the NEAT1 promoter in the p53wt cells, whereas no binding was 
observed in the p53ko cells which served as negative control. Binding to the p21 
promoter was used as positive control, showing the identical pattern with the exception 
of a contamination detected in the no-antibody control.  
 
Figure 34. ChIP-PCR for p53 binding in the promoter regions of NEAT1 and p21. Séraphine 
p53wt and p53ko cells treated with 10 µM nutlin-3 were used for ChIP. (A) 1.5% agarose gel 
showing high molecular weight DNA in unsheared samples, and successful shearing to 300 - 400 
bp in the samples used for ChIP. (B) Products of qRT-PCR for the NEAT1 promoter region (137 
nt) and p21 promoter region (positive control, 214 nt) were run on a 3% agarose gel. qRT-PCR 
products from a reaction run without template, with genomic DNA and without antibody selection 
(‘input’) served as controls. p53 antibodies from Santa Cruz (SC, p531) and BD (p532) were 
tested. Samples incubated with no antibody (noAb) were additional controls.  
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Combined with the data provided in section 3.6.2 this provides strong evidence for p53 
binding to the NEAT1 promoter, which results in transcriptional activation and expression 
of the NEAT1 gene. 
3.6.4 Summary of p53-dependent ncRNAs in CLL and BL 
By small RNA sequencing-based comparison of miRNA induction in TP53wt and 
TP53del/mut primary samples after DNA damage, miR-34a-5p was confirmed as prime p53 
target in CLL. A set of potential novel p53 targets was suggested including miR-182-5p, 
miR-7-5p and miR-320c/d, which show irradiation-triggered induction only in the wild-
type setting. In addition, this work’s data demonstrated p53-dependent lincRNA-p21 and 
NEAT1 regulation in primary CLL upon irradiation and nutlin-3 treatment. Figure 35 
provides an overview of DNA damage triggered expression changes of the top p53-
dependent RNAs assessed. In this hierarchical clustering, all TP53del/mut samples and 
most previously treated, high-risk TP53wt samples cluster together.  
In BL cell lines genetically modified for controlled p53 expression, both lincRNA-p21 and 
NEAT1 displayed TP53 status dependent induction upon nutlin-3, and direct p53 binding 
to the NEAT1 promoter was confirmed by ChIP-PCR. 
 
 
Figure 35. Unsupervised hierarchical clustering of p53 targets identified in primary CLL 
samples. The heatmap summarizes the irradiation (IR)-triggered fold induction of p53 targets 
(rows) NEAT1, lincRNA-p21 and p21 as determined by qRT-PCR, and NEAT1-002, NEAT1-202, 
miR-182-5p, miR-7-5p, miR-320d/c, miR-34a-5p and miR-34a precursor (pre-miR34a) as 
determined by sequencing for all samples of our test cohort (n = 34, columns). TP53 status of the 
samples is indicated. (●) Denotes previously treated TP53wt patients who had relapsed after 
chemotherapy. 
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4 Discussion 
The BCR- and p53 signaling pathways are key determinants of B-CLL tumor cell 
survival. BCR signaling is constitutively active in CLL cells56,83,84, eliciting survival 
supporting effects, while p53 is frequently deleted and/or mutated, leading to impaired 
tumor cell apoptosis and treatment resistance42,78. The involvement of ncRNAs in 
mediating these pro-survival and apoptotic effects is not well understood. To identify 
ncRNA networks dependent on BCR signaling and p53 pathway activation in primary 
CLL, a small RNA sequencing and analysis platform was established.  
Investigations of miRNA expression in primary CLL established the link between miRNA 
deregulation and cancer53. More extensive screens on miRNA expression in CLL have 
relied on quantification by microarray and qRT-PCR array technologies53,160,166-
169,190,266,267 confining the assessment of target RNA expression to sequences covered by 
the respective array. In contrast, sequencing based miRNA quantification allows the 
analyses to be continuously adapted to employ the most current reference databases for 
read mapping. The few studies that implemented RNA sequencing to quantify miRNA 
expression in CLL either used reference databases which contained still a limited 
number of sequences188,268, or were confined to a small number of CLL samples 
analysed (less than 10)188,227,232. This study therefore set out to use small RNA 
sequencing for a comprehensive quantification of miRNA expression in 35 primary CLL 
samples with a focus on dynamic expression upon BCR signaling inhibition or p53 
activation.  
By sequencing 82 samples from 35 CLL patients, 1244 mature miRNAs were detected. 
This greatly exceeds the 157 miRNAs detected by Landgraf et al.227 or the 256 miRNAs 
found expressed by Jima et al.232, who applied a similar analysis pipeline. In line with 
Jima et al., sequencing reads were mapped to the miRBase human reference 
sequences requesting perfect sequence identity. In contrast though, analyses for the 
present study did not exclude reads with more than 5 genomic matches. The challenge 
of dealing with multiple mapping reads was met by selecting only reads of 17 – 25 nt 
length for statistical analyses of miRNA expression, thereby excluding short sequences 
likely to map to the genome multiple times.  
After selecting ~15 to 35 nt RNA molecules for sequencing during library preparation, 
only 13% of reads generated corresponded to mature miRNA sequences, whereas 41% 
were not found in the RNA databases used (which did not include e.g. transponsons, 
non-lincRNA lncRNA and miRNA precursor sequences) or did not map to the genome. 
Considering the abundance of transposon transcripts and RNA splicing and editing, this 
percentage of non-mapping reads was expected. A considerable fraction of sequences 
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originated from transcripts > 50 nt, although 50 bp sequencing was performed. These 
possibly represent fragments originating from RNA degradation in the sample set 
(average RIN = 8.3). Unexpectedly, these sequences proved to be highly useful and 
informative.  
At baseline, miRNA expression in CLL was dominated by miR-21-5p, which accounted 
for 25% of all miRNA reads and is frequently found overexpressed in malignancies229-231. 
Eight of the 10 most strongly expressed miRNAs reported here were previously listed 
among the most abundant in primary CLL cells188, supporting the results of this work. 
Comparisons of baseline miRNA expression between CLL and normal CD19 positive B-
cells have been performed extensively53,160,168,269 and are therefore mentioned in this 
thesis only to evaluate the chosen sequencing approach. Interestingly, of those 10 most 
highly expressed miRNAs, miR-21-5p, miR-101-3p, miR-150-5p and miR-155-5p are 
known to be overrepresented in CLL versus normal B-cells isolated from peripheral 
blood188 and were confirmed in the present study. This overrepresentation was not 
observed in a comparison to miRNA expression in normal CD5+ memory B-cells168 
though, emphasizing the impact of the ‘normal counterpart’ chosen for profiling of 
aberrant miRNA expression. 
 
4.1 miRNA expression profiles predict IGHV status and associate with 
in vitro ibrutinib sensitivity 
The BCR signaling pathway is constitutively activated in freshly isolated B-CLL 
cells55,84,270, supporting tumor cell survival91,101 and providing an attractive drug 
target95,271. In this work, miRNAs involved in BCR signaling and response to inhibition by 
ibrutinib treatment in vitro were investigated, as they may play a role in BCR-signaling 
mediated CLL cell survival. To this end, IGHV status dependent miRNAs and miRNAs 
directly regulated upon in vitro ibrutinib treatment were identified, and miRNAs 
associated with treatment response were reported.  
Analyzing the basal expression of 35 primary CLL samples, 12 miRNAs were found 
differentially regulated based on IGHV status. Of those, the higher expression of miR-
155-5p and the lower expression of miR-29c-3p/5p in U-IGHV samples is in keeping with 
previous reports166,188,189,269. This study additionally found miR-547, -184, -330, -153 and 
-9 upregulated, and miR-514a, -141 and -4432 downregulated in U-IGHV samples. The 
pro-proliferative roles of miR-9 observed in mixed-lineage leukemia-arranged 
leukemia272, of miR-330 in glioblastoma273, of miR-153 in prostate cancer274 and of miR-
184 in squameous cell carcinoma275 are in line with higher expression in U-IGHV CLL. 
However, the targets of one miRNA are numerous and depend on cell type and 
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physiologic state, so that contrary findings exist276-278. A predictor encompassing the 
expression profiles of 15 miRNAs was calculated in this work, which was able to 
discriminate between M-IGHV and U-IGHV samples with 82% accuracy. Using miRNA 
expression profiles presents a potential alternative to IGHV sequencing as has been 
previously suggested187. However, the level of accuracy seen in this study does not 
support a substitution of sequencing by miRNA profiling in this cohort. 
Ibrutinib, a covalent inhibitor of Bruton’s tyrosine kinase (BTK) downstream of the BCR, 
leads to abrogation of CLL cell survival and has recently been approved for the treatment 
of relapsed CLL95,279. The basal expression of 10 miRNAs was found to differ based on 
in vitro ibrutinib sensitivity in 34 CLL samples. This included miR-574-5p, miR-24-3p, 
miR-23a-3p and miR-155-5p, implicating a correlation between low baseline sample 
viability and high ibrutinib sensitivity. miR-155-5p, miR-24 and miR-23b were previously 
described as higher expressed in U-IGHV166. miR-330-3p was added to this group, 
reflecting the established link between IGHV status and ibrutinib sensitivity.  
Samples expressing high miR-155-5p levels displayed particularly good ibrutinib 
sensitivity in vitro. Interestingly, high miR-155-5p levels associate with adverse clinical 
patient outcome and were demonstrated to enhance responsiveness to BCR ligation in 
CLL280, supporting CLL cell survival. Therefore, enhanced BCR signaling in miR-155-5p 
high expressing CLL could contribute to ibrutinib sensitivity of these samples. In contrast, 
high basal miR-150-5p levels mediated resistance to ibrutinib in vitro. Interestingly, miR-
150 was described to target FOXP1 (forkhead box P1) and GRB1 (GRB2-associated 
binding protein 1), enhancers of BCR signaling233. High miR-150-5p levels associated 
with low FOXP1 expression also in this work, and additionally with low PDIA6 
expression, which is predicted to be targeted by miR-150-5p and is induced upon BCR 
stimulation in CLL59. The negative impact of miR-150 on BCR signaling activity may 
explain the low effectivity of ibrutinib, which targets the same pathway. These two 
examples suggested that also other miRNAs associating with ibrutinib sensitivity could 
regulate BCR signaling activity and CLL cell survival. First support for this hypothesis 
was provided by observations of a negative correlation of miR-23a-3p (low in ibrutinib 
resistant samples) and FCRL2 expression. Predicted miR-23a-3p target FCRL2 is a 
transmembrane molecule specifically expressed in B lineage cells, is overexpressed in 
CLL with good prognosis237 and inhibits BCR signaling by recruitment of the inhibitory 
tyrosine phosphatase SHP-1 to the BCR236. Low miR-23a-3p expression could reduce 
BCR signaling activity via accumulation of FCRL2, contributing to ibrutinib resistance. 
Likewise, the expression of miR-574-5p (low in resistant samples) and its predicted 
target PIM3 inversely correlated. The kinase PIM3 is essential for CLL tumor cell 
survival281. Low miR-574-5p levels could therefore support cell survival and mediate 
Discussion 
76 
 
ibrutinib resistance through de-repression of PIM3 in CLL. These hypotheses provide an 
interesting starting point for further experimental work.  
 
4.2 BTK inhibition identifies a set of five BCR signaling-dependent 
miRNAs 
Until recently, regulation of miRNA expression by the complex BCR signaling cascade 
remained poorly investigated282. To identify BCR signaling dependent miRNAs, ibrutinib 
was used as a tool to abrogate BCR signaling in primary CLL. BCR signaling-induced 
miRNA expression was previously investigated by Pede et al.190, who evaluated the 
transcriptional response (mRNA, miRNA) of primary CLL cells upon anti-IgM mediated 
BCR stimulation in vitro using hybridization arrays and qRT-PCR. Stimulation with anti-
IgM targeting the BCR poses an unphysiological trigger to the receptor and it appeared 
more meaningful to inhibit steady-state, cell-autonomous BCR signaling55 for this work. 
Sequencing data analyses revealed an induction of miR-320c and miR-1246, while miR-
484, miR-17-5p, miR-155-3p and miR-27a-5p were downregulated. The p53-dependent 
induction of miR-320c observed upon DNA damage (refer to section 3.5.1) suggests that 
this regulation reflects ibrutinib treatment-induced apoptosis rather than a direct effect of 
BTK blockage. miR-155-3p has been found induced in the study of Pede et al., in line 
with our data. The miR-212/132-3p cluster was the only other miRNA regulated after 
BCR stimulation in their experiments. Interestingly, a reduction in miR-212 and miR-132-
3p expression was observed in this work, albeit the expression levels were extremely 
low. This questions the biological relevance of the published miR-212/132-3p induction 
upon BCR signaling. 
The repression of oncogenic miR-17-5p upon BTK inhibition is in keeping with ibrutinib’s 
effects of abrogating CLL cell survival and proliferation. Overexpression of the miR-
17~92 cluster is known to induce lymphoma-/leukemogenesis in transgenic mice283 and 
has been described to amplify BCR signaling in diffuse large B-cell lymphoma by 
augmenting BCR downstream target activation including PLCγ2 phosphorylation and 
calcium flux284. The present work suggests a role of miR-17-5p in BCR signaling also in 
CLL, acting to support tumor cell survival and proliferation.  
Previously, miR-155-5p expression was suggested to be BCR dependent as implied by 
the coexistence of miR-155-5p overexpression and over-active BCR signaling in CLL vs. 
healthy B-cells181,269,285 and an induction of miR-155-5p after BCR stimulation of healthy 
B-cells and Burkitt’s Lymphoma cell lines269,286. Neither Pede et al. nor this work found 
miR-155-5p expression to be BCR signaling dependent. However, an association 
between high miR-155-5p expression, high ibrutinib sensitivity and U-IGHV status was 
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apparent. Therefore, this study rather supports miR-155-5p as a recently suggested 
enhancer280 than as a target of CLL B-cell receptor signaling. 
For miR-484 and miR-1246 no connection to BCR signaling or support of cell survival 
has been previously reported.  
In general, very subtle regulations of miRNA expression upon BTK inhibition were 
observed (0.5 to 1.4 fold), indicating a low level of baseline BCR signaling activity. This 
suggests that inhibiting baseline, cell-autonomous BCR signaling without applying 
extrinsic BCR stimulation comes at the expense of low downstream regulation 
amplitudes and the possibility of missing BCR signaling targets. Additionally, ibrutinib 
has been shown to act in vitro within 8 hours as read out by CD69 expression, cell 
viability and caspase-3 activation100, so a shorter incubation time (e.g. 12 hours) might 
enrich the results for more immediate BCR signaling targets.  
 
4.3 miR-182, miR-7 and miR-320d/c are novel p53-dependent miRNAs in 
CLL 
miRNA targets of p53 were previously reported for various cellular models and cancer 
entities. They will not be reviewed here for their sheer number, but were recently 
summarized by Hermeking287. It needs to be kept in mind though, that the set of 
functional p53 targets will vary with the cell type and the type of stress applied to trigger 
p53 activation208,288. In CLL, several studies have gathered associative data of basal 
miRNA expression levels and 17p status169,191,266. However, a direct regulation of 
aberrantly expressed miRNAs by p53, as can be demonstrated by analysis of miRNA 
expression changes upon p53 activation, was not investigated.  
Upon DNA damage, higher rates of apoptosis and expression of key p53 targets p21 and 
miR-34a-5p was observed in TP53wt than in del11q than in TP53del/mut samples. Further, 
miR-34a-5p expression was already significantly lower in TP53del/mut than TP53wt already 
at baseline. This was in line with previous data70,116,170,289 and affirmed the capability of 
the experimental approach chosen.  
Quantification of miRNA expression dynamics upon DNA damage demonstrated a more 
dynamic overall response to irradiation-triggered p53 induction in TP53wt than TP53del/mut 
samples. Still, a few miRNAs including miR-150-3p, miR-155-5p and miR-21-3p were 
found regulated in both sample groups, implying a role in DNA damage response 
independent of p53. miR-34a-5p, miR-182-5p, miR-7-5p and miR-320d/c were identified 
as the top five p53-dependent miRNAs. The miRNAs were checked for shared 
sequences, and a false-positive induction caused by a random RNA fragment mapping 
to all of them was excluded. Interestingly, for the four last-mentioned, basal expression 
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levels were higher in TP53del/mut than TP53wt samples, which is in contrast to miR-34a-5p 
and seems counter-intuitive when considering p53-dependency. However, TP53 status 
dependent miRNA induction was validated by qRT-PCR for miR-7-5p and miR-320d (in 
addition to miR-34a-5p). Previous observations support p53-dependent expression of 
these miRNAs. miR-182-5p has been described as p53 target in lung, breast and colon 
cancer cell lines193,290, and its anti-proliferative activity was demonstrated in renal cell 
carcinoma291. For miR-7-5p, a p53 binding site was identified in close proximity to miR-7-
2206, and an anti-proliferative, cell cycle arresting292,293 function in solid cancers 
underlines its tumor suppressive role and supports p53-dependent transcription. 
Experimentally validated targets of miR-7-5p include members of the AKT pathway (IRS-
1 and 2) in glioblastoma294 and transcriptional repressor YY1 (yin yang 1) in colorectal 
cancer292 to induce apoptosis and inhibit cell proliferation. miR-320d/c/b display high 
sequence homology, similar regulation and belong to the miR-320 family sharing the 
same seed sequence. For miR-320, no direct functional link to p53 has been established 
to date, although p53 binding sites in proximity to miR-320c and b were reported207. 
Zhang et al.295 found miR-320 in regions with DNA copy number loss in three different 
types of solid cancer (breast, ovarian, melanoma), and Schepeler et al.296 established 
miR-320 as independent predictor in colon tumors, where high expression correlated 
with a longer progression-free survival. In summary, this suggests a role of miR-182-5p, 
miR-7-5p and miR-320d/c in apoptosis and inhibition of cell proliferation as part of the 
p53 pathway in primary CLL, a connection which was uncovered by this work.  
Eighteen further miRNAs displayed p53-dependent expression, of which miR-34a-3p (as 
part of pre-miR-34a) and miR-15a-5p are published p53 targets in CLL70,116,297. p53 has 
been shown to activate transcription of mir-155195, and was reported to bind in the 
proximity of mir-9-2207, mir-23a206-208, mir-29b208 and mir-26a-2208 in various cell lines. 
Functional studies of their p53-dependence are lacking.  
Interestingly, irradiation-triggered induction of oncogenic miR-17~92 cluster members 
(miR-17, miR-18a and miR-20a but not miR-92a) was stronger in TP53del/mut than TP53wt 
samples. This could result from a decreased miR-17~92 repression by p53298. Similarly, 
miR-155-3p was stronger induced in TP53del/mut than than TP53wt samples. Considering 
its downregulation after survival-abrogating ibrutinib treatment, it could confer a survival 
advantage to TP53del/mut cells, although its rather low expression is to be beared in mind. 
Table 12 summarizes miRNAs that were previously reported to display significantly 
different basal expression levels between 17p13 disomic and 17p13 deleted patients. 
This work’s data support and confirm p53-dependency of miR-34a-5p expression, since 
lower basal levels were observed in del17p patients and a higher DNA-damage triggered 
induction was seen in TP53wt than TP53del/mut. Along the same lines, evidence for p53-
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dependency of miR-15a suppression is provided by a significant IR-mediated 
suppression exclusively in the wild-type setting. In contrast, this work’s results suggest 
that the lower expression of miR-151a-3p, miR-29c, miR-181b and miR-497 in del17p is 
a p53-independent effect, possibly resulting from the deletion of another gene on 17p, as 
no regulation is observed upon p53 induction. This can be underlined for miR-497, which 
itself is located on 17p approximately 200 kb centromeric of TP53 and hit by 17p 
deletions as a ‘bystander’266. For miR-17-5p and miR-155-5p, DNA damage triggered 
induction independent of TP53 status suggests a p53-independent role in the DNA 
damage response. 
 
Table 12. p53 dependence of miRNAs with reported differential basal expression in deleted 
versus disomic 17p in CLL. Observed data were derived from the small RNA sequencing 
screen on 15 tumor samples from previously untreated TP53wt and 10 TP53del/mut patients. FC = 
fold change. IR = irradiation, 5 Gy (cell harvest 24h thereafter). P-values were Benjamini-
Hochberg corrected. 
miRNA 
name 
Reported 
level in  
del17p 
Observed 
FC del vs. 
disomic 
17p 
p-
value 
Regu-
lation by 
IR in 
TP53wt 
p-value 
Regu-
lation by 
IR in 
TP53del/mut 
p- 
value 
miR-34a-5p 
Low115,167,
189,262 
0.3 0.16 4.3 4.3E-39 2.9 2.3E-04 
miR-151a-3p Low169 0.2 0.16 1.0 0.91 1.0 0.99 
miR-29c Low167,189 0.6 0.51 1.0 0.77 1.0 0,94 
miR-17-5p Low191 0.9 0.90 1.2 0.03 1.4 1.3E-04 
miR-181b Low266 1.1 0.94 1.1 0.21 1.1 0.94 
miR-497 Low266 1.1 0.95 0.9 0.81 0.9 0.98 
miR-155-5p High266 1.4 0.43 1.4 6.2E-07 1.3 3.6E-04 
miR-21-5p High266 1.2 0.70 0.9 0.28 1.0 0.93 
miR-15a High266 0.7 0.75 0.8 0.02 1.1 0.93 
 
Detailed insight into the biological role of miRNAs can only be gained through 
characterization of their mRNA target genes, which enables the discovery of their 
mechanism of action. A targeted quantification of mRNA expression was not part of this 
work. However, 13% of the small RNA reads generated here mapped to mRNA 
sequences. Those reads are expected to be fragments arising from RNA degradation, 
which was present at low levels after RNA isolation as indicated by an average RNA 
integrity number of 8.3. In these fragments, a clear TP53 status dependent induction of 
key p53 transcriptional targets including MDM2, p21, Bax, Puma and GADD45A was 
observed. This suggested that their levels were representative of the expression of 
Discussion 
80 
 
longer parent transcripts, enabling the identification of p53-dependent long (non-coding) 
RNA transcripts from this dataset.  
Accordingly, for the top five p53-dependent miRNAs (miR-34a-5p, miR-182-5p, miR-7-
5p, miR-320d/c), predicted mRNA targets displaying an IR-triggered regulation inverse to 
the miRNA expression dynamics were identified. This provides a starting point for 
experimental validation and subsequent functional analyses.  
 
4.4 p53-dependent long non-coding RNAs identified in primary CLL and 
BL cell lines 
4.4.1 p53-dependent lincRNA-p21 expression in CLL and BL 
The present work demonstrates a very low expression of lincRNA-p21 in CLL, which is 
strongly induced upon p53 induction by irradiation or nutlin-3 treatment in p53 wild-type 
samples only. Induction of apoptosis, p21 and lincRNA-p21 were shown to closely 
correlate. TP53 status dependency of lincRNA-p21 induction was confirmed in a set of 
Burkitt’s Lymphoma cell lines. p53 knockdown or CRISPR/Cas9-mediated p53 knockout 
abolished lincRNA-p21 induction, proving direct p53-dependency. These data argue for 
a role of lincRNA-p21 in the p53 pathway in CLL and lymphoma albeit the question 
remains, whether this is limited to a co-activation of p21299, or whether it is (additionally) 
acting beyond on a plethora of downstream targets of the p53 pathway205. The present 
experiments were not designed to dissect the independence of p21 and lincRNA-p21 
transcription. 
Long non-coding RNAs have been implicated in the p53 network as regulators and 
effectors of p53. Only a handful of lncRNA p53 targets have been described in more 
detail, and the relevance to CLL biology remained unknown. LincRNA-p21 was one of 
the first lncRNA p53 targets to be characterized in mouse endothelial fibroblasts204. It 
obtained its name for its proximity to the neighboring p21 gene, but was proposed to be 
transcribed independently from p21204 to mediate transcriptional suppression (e.g. of 
stat3, cyclin D2, cyclin dependent kinase 4) downstream of p53 via several mechanisms 
in trans205. Very recently, lincRNA-p21 was shown to activate p21 transcription in cis, 
acting primarily as a locus-restricted coactivator for p53-mediated p21 expression, which 
contrasts previous findings299. p53-dependent transcription of lincRNA-p21 was 
confirmed in various solid cancer cell lines (HCT-116300, HeLa and MCF-7301). In primary 
human material, lincRNA-p21 was found at decreased levels in plasma of CLL patients 
as opposed to healthy individuals302, and decreased in colon tumor versus normal 
colonic tissue300, which is consistent with a tumor-suppressive function.     
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4.4.2 p53-dependent NEAT1 expression in CLL and BL 
NEAT1 (nuclear enriched abundant transcript 1) clearly emerged as potential p53 target 
from sequencing-based analysis of non-coding RNA expression other than mature 
miRNA. More precisely, of the three NEAT1 transcripts in the reference database 
(Ensembl GRCh37), the largely overlapping NEAT1-002 and -202 transcripts (~1.7 and 
~1.5 kb) were found induced. TP53 status dependent NEAT1 induction was validated by 
qRT-PCR. Since the discovery of NEAT1, confirmed transcript sizes and numbers have 
been subject to numerous changes, amounting to five since the latest Ensembl update in 
August 2014 (Emsembl GRCh38). This discussion will consider aggregated NEAT1 
expression as determined by qRT-PCR (Figure 26 A). 
p53-dependence of NEAT1 expression was further supported by a close correlation to 
p21 expression and TP53 status dependent response to nutlin-3 treatment in primary 
CLL. TP53 dependent expression was confirmed in genetically modified Burkitt’s 
lymphoma cell lines displaying controlled p53 activity, and a p53 ChIP-PCR experiment 
finally demonstrated direct, TP53 status dependent binding of p53 to the NEAT1 
promoter sequence.  
NEAT1 is a lincRNA widely expressed across cell types upon differentiation303, where it 
localizes to the nucleus. It is an essential architectural component of paraspeckles, 
relatively newly identified ribonucleoprotein bodies that are found in the interchromatin 
space of mammalian cells upon differentiation263,304-306. NEAT1 is the only RNA 
component in human paraspeckles, building a scaffold for 40 co-localized proteins307. 
Knockdown of NEAT1 led to paraspeckle loss263, demonstrating that its RNA, but not the 
associated proteins, is the rate-limiting molecule for paraspeckle formation. In mice, 
paraspeckles were non-essential in unstressed conditions308. As NEAT1 upregulation 
was observed upon proteasomal inhibition, serum starvation, acidosis and HIV infection 
in vitro, a role in the cellular stress response has been suggested213,309.  
Binding of p53 to the NEAT1 promoter has been observed in two previous large-scale 
p53 ChIP-Seq studies: Botcheva et al.206 reported the NEAT1 promoter as novel p53 
binding site in a human lung fibroblast cell line, which was confirmed in mouse 
endothelial fibroblasts310. It was not until very recently though, that p53 binding at this 
locus was demonstrated to be functional, i.e. induce transcription of the nearby NEAT1 
gene209. The present work now demonstrates a stress-induced transcriptional activation 
of NEAT1 by p53 in leukemia and lymphoma. In light of the aforementioned, this poses 
the question about the role of NEAT1 upregulation upon p53 activation in the DNA 
damage response or, asked differently, the role of NEAT1 in mediating p53 pathway 
function.  
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Paraspeckles can influence gene expression through three mechanisms: On the one 
hand, they control nuclear retention of mRNAs containing inverted repeats (Alu 
elements) that form double-stranded RNA regions subject to adenosine-to-inosine (A-to-
I) editing by ADARs (adenosine deaminases acting on RNA), ultimately resulting in 
translational repression304. On the other hand, they counter-regulate the function of 
paraspeckle-localizing proteins, which normally regulate distinct nuclear processes 
outside the paraspeckles, as recently demonstrated for SFPQ (splicing factor 
proline/glutamine-rich)311,312. Thirdly, NEAT1 has been described to bind to active 
chromatin sites, its localization being subject to transcriptional status rather than 
homology to the DNA sequence. It was speculated, that NEAT1 could play a structural 
role in the organization of nuclear bodies at highly transcribed loci, although it remained 
unclear how this would impact on gene expression profiles313. 
Considering the role of NEAT1 in the control of hyperedited mRNA expression, p53 
activation potentially impacts on the expression of hundreds of genes containing Alu 
repeats in their 3’-UTRs that undergo A-to-I editing. The impact of p53-mediated 
translational repression via NEAT1-mediated nuclear retention of (hyperedited) mRNA 
could be characterized by screening the subcellular localization of mRNA and 
corresponding protein levels after p53 activation. Thereby, NEAT1 overexpression could 
explain repressive effects seen upon p53 activation314, whose mechanisms remain 
largely unknown142,315. Another potential connection between p53 and NEAT1 expression 
emerges from the re-localization of paraspeckle proteins from the nucleoplasm into the 
paraspeckles upon NEAT1 overexpression263,311,312. In the nucleoplasm, these proteins 
serve diverse functions including transcriptional control, RNA processing and DNA 
repair311,316. Interestingly, upon DNA damage, the paraspeckle proteins SFPQ, NONO 
(non-POU domain-containing octamer-binding protein) and FUS (fused in sarcoma) are 
rapidly recruited to the damaged sites, where the SFPQ supports homology-directed 
double-strand break repair317,318. In line with this observation, reduced SFPQ expression 
conferred cellular sensitivity to DNA damaging agents. A combination of SFPQ depletion 
with a deletion of Rad51d (catalyzing homologous pairing between single- and double-
stranded DNA) resulted in a lethal phenotype as would be expected from a disruption of 
homologous recombination (HR)318. FUS depletion diminished double-strand break 
repair by HR and non-homologous end joining (NHEJ)77. Similarly, paraspeckle protein 
RBM14 (RNA binding motif protein 14) was shown to stimulate DNA repair by controlling 
the NHEJ pathway. Accordingly, its upregulation caused radio resistance in 
glioblastima319. It is tempting to hypothesize that p53-mediated NEAT1 induction would 
sequester SFPQ, FUS and RBM14 away from their sites of action, resulting in a 
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disruption of HR and NHEJ, tilting the p53-response from DNA damage repair to 
apoptosis.  
However, considering NEAT1 is also induced upon direct p53 activation by nutlin-3 in 
absence of DNA damage, it would be expected to regulate responses beyond DNA 
damage repair. A connection between p53 activation, NEAT1 induction and inhibition of 
paraspeckle protein activity or nuclear export of A-to-I edited RNA to apoptosis as 
suggested here has not been established and opens an interesting field of study. 
 
In summary, this work confirmed miR-34a as prime p53 target and identified several 
novel p53 targets in CLL including miR-182-5p, miR-7-5p and miR-320d/c. While some 
reports indicating p53-dependency of miR-182-5p, miR-7-5p in other entities exist, this 
context is novel for miR-320d/c. With the exception of miR-15a and miR-34a, miRNAs 
previously reported to associate with p53 aberrations in CLL were regulated 
 
Figure 36. Summary of p53 targets identified in CLL. miR-34a-5p was confirmed as non-
coding p53 target. miR-182-5p, miR-7-5p and miR-320c/d are newly suggested targets in CLL, 
which are induced less strongly. NEAT1 and lincRNA-p21 are novel long non-coding p53 targets 
in CLL and Burkitt’s lymphoma. The roles of the newly identified ncRNAs in mediating the 
outcome of p53 activation needs further study. In addition, a selection of known p53 targets also 
found in this work is presented. MDM2, mouse double minute 2 homolog; DDB2, damage-specific 
DNA binding protein 2; ASCC3, activating signal cointegrator 1 complex subunit 3, GADD45A, 
growth arreast and DNA-damage-inducible alpha; Puma, p53 upregulated modulator of apoptosis; 
BCL-2 associated X protein; TNFRSF10B, tumor necrosis factor receptor superfamily, member 
10B.   
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independently of TP53 status. Beyond miRNA, the smRNA sequencing dataset reflected 
the p53-dependency of key p53 targets including MDM2, p21, Bax and Puma, and was 
therefore used to evaluate long ncRNA expression. The lincRNAs NEAT1 and lincRNA-
p21 were found p53-dependently induced in CLL and Burkitt’s lymphoma. Considering 
the high expression levels of NEAT1 and the absence of a previous link to cancer 
chemoresistance, it appeared a particularly interesting target. p53 binding to the 
promoter sequence of NEAT1 was demonstrated. The function of NEAT1 upon p53 
induction remains unknown. However, NEAT1 binding partners were previously implied 
to be critical for DNA damage repair, suggesting a role for p53-induced NEAT1 in tilting 
the balance from damage repair to apoptosis. A graphical summary is provided in Figure 
36. 
 
4.5 CLL high-risk patients display p53 pathway impairment independent 
of TP53 and ATM aberrations  
The reasons for chemorefractoriness in CLL patients displaying wild-type, disomic TP53 
and ATM are not well understood. By analysis of irradiation-triggered induction of p21, 
lincRNA-p21, NEAT1, miR-182-5p, miR-7-5p and miR-320d/c to assess p53 signaling 
activity in samples of TP53wt, previously treated ‘high-risk’ patients, a pattern similar to 
p53 pathway inactivation was found despite disomic wild-type p53 and ATM. In this 
setting of impaired p53 activity, miR-34a-5p induction was not reduced in the high-risk 
group, which might be due to p53-independent, alternative regulation, whose existence 
has been previously suggested193,320,321. While p53 pathway inactivation offers an 
explanation for the observed chemorefractoriness, no reason for p53 inactivation could 
be found on the basis of ncRNA regulation, i.e. no aberrant expression of ncRNAs 
reported to target p53 pathway members were identified. Thus, the mechanism 
underlying impaired p53 pathway activity in this patient group warrants further study. 
However, the development of high-risk disease can (additionally) be caused by 
deregulation of tumor suppressors and oncogenes other than p53, as recently suggested 
by the identification of genetic aberrations affecting BIRC3 (Baculoviral IAP repeat 
containing 3) and FAT1 (protocadherin Fat 1), which closely associated with 
chemorefractoriness in TP53wt CLL322,323.  
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5 Conclusion and Perspective 
Active B-cell receptor signaling supports the survival of CLL tumor cells, and p53 
aberrations are known to confer resistance towards apoptosis, mediating poor prognosis. 
We hypothesized that by modulating the BCR- and p53 signaling pathways, miRNAs and 
other ncRNAs could be identified that play important roles in mediating their outcome, 
and are critical to survival or apoptosis of CLL tumor cells. 
 
In this work, small RNA sequencing was applied to assess ncRNA expression in CLL at 
unprecedented resolution. miRNAs were identified that are IGHV mutation status 
dependently expressed, regulated upon abrogation of BCR signaling and/or show basal 
expression levels associated with in vitro ibrutinib sensitivity. All of those are potentially 
involved in supporting CLL cell survival. Direct BCR signaling dependent expression was 
demonstrated for miR-320c, miR-1246, miR-484, miR-17-5p, miR-155-3p and miR-27a-
5p. Their influence on tumor cell survival would be most interesting to investigate further 
by targeted modulation of expression levels.  
The emphasis of this work was put on the identification of p53-dependent ncRNAs. By 
analyzing ncRNA expression changes upon DNA damage-triggered p53 induction, a set 
of miRNAs were discovered as novel p53 targets in CLL. Beyond known prominent p53 
target miRNA-34a these included miR-182-5p, miR-7-5p and miR-320d/c. Experimentally 
validating the suggested mRNA targets of those miRNAs will be critical to understand 
underlying functional mechanisms and evaluate their potential for miRNA-based 
therapies. Importantly, the present work demonstrates p53-dependent induction of 
lincRNA-p21 and NEAT1 in CLL and Burkitt’s lymphoma, providing first evidence of p53-
dependent long non-coding RNA regulation in these entities. p53-dependent induction of 
lincRNA NEAT1, a key component of nuclear paraspeckles, is intriguing, and the 
involvement of paraspeckles in p53-dependent apoptosis opens a new field of study.  
These findings extend the network of p53-regulated genes in CLL and lymphoma. 
Subsequent work will need to elucidate the functional roles of the newly identified p53 
targets. 
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Appendix 
Table S1. Detailed sample genetics and grouping for comparison of ncRNA expression. 
Group 1 = TP53wt patients without del11q, no prior treatment; group 2 = TP53wt ‘high-risk’ 
patients, previously treated; group 3 = TP53del/mut patients. Y = yes, N = no. *A sample containing 
6% TP53 mutation was considered TP53wt. 
group Sample Nr. 
del17p,  
% 
TP53mut, 
% 
del11q,  
% 
other,  
% IGHV 
Prior 
treatment 
1 
1 0 0 0 MYD88, 65  M N 
2 0 0 0 tris12, 78  UM N 
3 0 0 0 0 UM N 
4 0 0 0 0 UM N 
5 0 0 0 0 M N 
6 0 0 0 0 M N 
7 0 0 0 0 UM N 
8 0 0 0 0 M N 
9 0 0 0 0 M N 
10 0 0 0 0 M N 
11 0 0 0 0 M N 
12 0 0 0 0 UM N 
13 0 0 0 0 M N 
14 0 0 0 0 M N 
15 0 0 0 tris 12, 57 M N 
2 
16 0 0 95 BRAF, 12  UM Y 
17 0 0 88 NOTCH1, 45  UM Y 
18 0 0 81 SF3B1, 48  UM Y 
19 0 0 79 ATM, 37 UM Y 
20 0 0 0 SF3B1, 34 UM Y 
21 0 0 0 8q24+, 78; SF3B1, 45 M Y 
22 0 6 11 SF3B1, 34  M Y 
23 0 0 0 8q24+, 78  M Y 
24 0 7 0 ATM, 33 UM Y 
3 
25 13 71 0 0 M Y 
26 23 26 0 0 UM Y 
27 Y 30 0 NOTCH1, 50  UM Y 
28 91 0 0 MYD88, 50  M N 
29 Y 54 0 SF3B1, 52; BRAF, 49 UM Y 
30 58 44 0 0 M Y 
31 11 35 0 BRAF, 17; SF3B1, 44 UM Y 
32 52 80 0 0 UM N 
33 ? 44 0 SF3B1, 48 UM Y 
34 47 92 0 0 UM Y 
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Table S2. TP53 mutation status of the BL cell lines used. 
Cell line TP53 status Amino acid change 
BL-2 wt - 
BL-7 wt - 
Cheptanges wt - 
Ly-47 wt - 
Salina wt - 
Seraphine wt - 
BJAB c.578A>G p.H193R 
BL-60 c.742C>T; c.844C>T p.R248W; p.R282W 
CA-46 c.743G>A p.R248Q 
Namalwa c.743G>A p.R248Q 
Ramos c.760_761AT>GA p.I254D 
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Table S3. Comparison of the 30 highest expressed miRNAs in CLL baseline samples to 
previously reported CLL sequencing screens. Normalized read counts are provided. 
 This work Jima et al.232 Landgraf et al.227 
rank name 
average 
read count 
NT 
name 
average 
read count 
NT 
name 
average 
read count 
NT 
1 miR-21-5p 531914 let-7f-1 1166618 miR-142-3p 247 
2 miR-26a-5p 234464 let-7g 841349 miR-142-5p 165 
3 let-7g-5p 206540 let-7a-2 358095 miR-29b-3p 112 
4 miR-101-3p 160967 miR-21 215094 miR-16-5p 85 
5 miR-150-5p 136475 let-7i 174294 miR-150-3p 70 
6 miR-148a-3p 112555 miR-140-3p 170300 miR-26a-5p 61 
7 let-7f-5p 93963 miR-29a 116065 miR-21-5p 55 
8 miR-29a-3p 84091 miR-101-1 93093 miR-30e-5p 37 
9 let-7i-5p 74492 miR-142 54372 miR-15a-5p 35 
10 miR-155-5p 63073 miR-378 43937 miR-29a-3p 33 
11 miR-142-3p 34047 miR-103-1 43831 miR-26b-5p 24 
12 miR-142-5p 31798 miR-320c-1 32030 let-7f-5p 22 
13 let-7a-5p 31678 miR-320a 30631 let-7a-5p 19 
14 miR-26b-5p 31105 miR-101-2 29796 miR-101-3p 18 
15 miR-27a-3p 29320 miR-103-2 27408 miR-30d-5p 17 
16 miR-30d-5p 23499 miR-107 25865 miR-155-5p 15 
17 miR-92a-3p 20473 miR-423 24503 mir-29c-3p 13 
18 miR-16-5p 20436 miR-25 20142 miR-140-5p 12 
19 miR-103a-3p 19451 miR-26b 19647 let-7g-5p 8 
20 miR-191-5p 18884 miR-26a-1 18373 miR-28-5p 7 
21 miR-20a-5p 18854 miR-92a-1 14005 let-7i-5p 6 
22 miR-361-3p 17263 miR-30e* 11068 miR-32-5p 5 
23 miR-1246 16815 miR-221 10882 miR-191-5p 5 
24 miR-30e-5p 14928 miR-30e 8944 miR-27a-3p 5 
25 miR-29b-3p 12868 miR-191 7248 miR-19b-3p 4 
26 miR-140-3p 11523 miR-16-1 7239 miR-186-5p 3 
27 miR-25-3p 10692 miR-192 6898 miR-146a-5p 3 
28 miR-186-5p 9726 miR-29c 5770 miR-24-3p 3 
29 miR-30b-5p 9225 miR-30d 5456 miR-92a-3p 3 
30 miR-146a-5p 9197 miR-151-3p 4801 miR-30c-5p 3 
 
  
Appendix 
106 
 
Table S4. mRNAs inversely correlating to miR-574-5p expression, and predicted to be 
targeted by miR-574-5p. Target prediction was performed by miRWalk, miRanda and 
TargetScan algorithms. Pearson’s correlation coefficient (R) is provided and p-values corrected 
for multiple testing are provided. 
Gene / protein name R p-value 
SLC16A14 / solute carrier family 16, member 4  -0.67 0.009 
IMPACT / impact RWD domain protein -0.65 0.010 
MLLT3 / myeloid/lymphoid or mixed-lineage leukemia translocated to, 3 -0.64 0.012 
PIM3 / PIM3 -0.64 0.013 
CLDN6 / claudin-6 -0.62 0.016 
DCDC2 / doublecortin domain-containing protein 2 -0.61 0.017 
PHOSPHO1 / phosphatase, orphan 1 -0.61 0.017 
LECT1 / chondromodulin-1 -0.59 0.023 
SLIT2 / slit homolog 2 -0.58 0.028 
STXBP5L / syntaxin-binding protein 5 -0.57 0.030 
MAOB / monoamine oxidase B -0.56 0.031 
MYO5B / myosin V B -0.56 0.035 
TRMT5 / tRNA methyltransferase 5 -0.55 0.036 
GPR83 / orphan receptor Gpr83 -0.55 0.037 
TLN2 / talin 2 -0.55 0.039 
NSL1 / kinetochore-associated protein NSL1 homolog -0.55 0.040 
FOXO4 / forkhead box O4 -0.54 0.040 
HOXC8 / homeobox C8 -0.54 0.041 
XPO-7 / exportin-7 -0.54 0.042 
INSIG1 / insulin induced gene 1 -0.54 0.043 
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Table S5. ncRNAs differentially expressed between previously untreated TP53wt and high-
risk TP53wt samples at baseline. Previously untreated TP53wt samples (UT, n = 15) were 
compared to high-risk TP53wt samples that had all received prior treatment (PT, n = 9). Mean 
normalized read counts and Benjamini-Hochberg corrected p-values are provided. 
RNA identifier RNA 
type 
UT TP53wt PT TP53wt Fold 
difference 
p-value 
ENSG00000201570 snRNA 2407 32 0.01 1.3E-4 
ENSG00000245526 lincRNA 225 1718 7.56 0.009 
ENSG00000261786 lincRNA 117 6 0.05 0.009 
ENSG00000230590 lincRNA 314 23 0.06 0.009 
miR-1285-3p miRNA 21 36 1.86 0.014 
let-7b-5p miRNA 3343 7523 2.17 0.026 
ENSG00000201198 snRNA 65 21 0.33 0.019 
ENSG00000239075 snRNA 51 14 0.25 0.019 
ENSG00000207227 snRNA 50 14 0.26 0.032 
ENSG00000206595 snRNA 51 14 0.26 0.034 
ENSG00000207099 snRNA 85 31 0.36 0.042 
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Figure S1. Induction of the top four p53-dependently regulated miRNAs upon irradiation. 
NT = non-treated, IR = irradiated. Normalized read counts and Benjamini-Hochberg corrected p-
values are provided. One colour encodes one specific TP53wt or TP53del/mut sample.  
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